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Abstract 
 
Chronic Probiotic Supplementation and its Effects on eHsp72 and LPS 
Concentration Following a Desert-based Ultramarathon 
 
By 
 
Hannah Marshall  
 
This study investigated the effect of 12wk probiotic supplementation on the 
Lipopolysaccharides (LPS) and extracellular-heat-shock-protein 72 (eHsp72) 
response to a 7d ultra-endurance event (249.4km) in extreme heat [(average 
temperature ~38°C) Marathon des Sables (MDS) 2015]. Thirty-two (6 female) 
competitors were randomly allocated to receive probiotic, probiotic + glutamine, or 
no supplementation for 12wk prior to the MDS. Blood samples were collected on 
two occasions prior to the race [12wk (baseline) and 7d pre-race], and two further 
occasions post-race (6-8h and 7d post-race). Plasma eHsp72 and LPS concentrations 
were determined using ELISAs; V O was recorded at baseline and pre-race. A 
significant increase in overall mean V O was observed from baseline to pre-race 
(p<0.05), however no difference was found between groups (p>0.05). Overall mean 
post-race eHsp72 concentration was significantly increased (p<0.05) by 124% from 
baseline, there was no significant effect of group on eHsp72 concentration at any 
time point (p>0.05). There was no significant change in LPS concentration from 
baseline to post-race in all groups (p>0.05), no difference in LPS concentration was 
observed between groups at any time (p>0.05). This study indicates an ineffective 
role of PRO and PGLn supplementation on LPS translocation and eHsp72 response 
to ultramarathon performance in extreme heat. 
 
Key words: Ultra-endurance; extracellular heat shock protein 72; 
lipopolysaccharides; probiotics 
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CHAPTER 1: General Introduction 
 
Strenuous physical activity and/or extremes of environmental temperature can 
decrement physical (DeMartini et al., 2014; Kark et al., 1996; Peiffer and Abbiss, 
2011) and cognitive performance (Taylor et al., 2015), with their combination 
(exercise heat-stress) an acknowledged risk factor for development of exertional heat 
illnesses [EHI; (Armstrong et al., 2007)]. Implicated within exertional heat stress 
(EHS) and EHI pathophysiologies are a plethora of physiological responses which 
initially act to protect the body from damage [e.g. heat shock protein (HSP) increases 
(Asea et al., 2000) amongst others], yet if the exercise heat-stress is not resolved, 
negative physiological responses can be experienced, including the presentation of 
endotoxemia (Brock-Utne et al., 1988; Ng et al., 2008; Selkirk et al., 2008). 
Athletes, military personnel, and occupational workers can be exposed to exercise 
heat-stress acutely or chronically dependent on the environment their prescribed task 
or pursuit is to be completed within. 
 
The highly inducible isoform of the HSP 70 kDa family HSP72 [HSPA1A 
(Kampinga et al., 2009)], at both the gene (Hsp) and protein (HSP) level, robustly 
increases in response to exercise heat-stress (Gibson et al., 2015b; Périard et al., 
2012; Ruell et al., 2014; Selkirk et al., 2009), having a high affinity for denatured 
protein [e.g. heat-induced protein homeostasis disturbance (Mayer and Bukau, 
2005)] and functions to resist thermal stress induced cell necrosis (Takayama et al., 
2003). The cytoprotective influence of Hsp72 [and other Hsps, e.g. Hsp27 
(Concannon et al., 2003) and HSP90 (Richter and Buchner, 2001)] principally 
involves the chaperoning and refolding of mis-folded and denatured proteins (Gabai 
and Sherman, 2002). Hsp72/HSP72 have been detected in both the intracellular 
(iHsp72) and extracellular (eHsp72) environments with ‘gene’ [typically mRNA 
(Gibson et al., 2015a; Tuttle et al., 2015)] Hsp72 released from the cell, whereas 
intracellular [iHSP (Périard et al., 2015; Taylor et al., 2010b)] and extracellular HSP 
[eHSP (Kampinga et al., 2009; Tavaria et al., 1996)] denote the protein within their 
respective environments. These iHSPs are well characterised as molecular 
chaperones, with iHsp72 and iHSP72 strongly correlating with in vivo cellular and 
whole body tolerance to thermal stress (Magalhaes et al., 2010; McClung et al., 
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2008; Selkirk et al., 2009). In contrast to iHSP72, eHSP72 function in vivo is poorly 
characterised with high inter- and intra-individual variation, albeit increasing in 
response to a number of stressful situations, including exercise (Febbraio et al., 
2002a; Walsh et al., 2001), heat-stress (Lovell et al., 2007), exercise heat-stress 
(Gibson et al., 2014) and trauma (Dybdahl et al., 2002; Pittet et al., 2002). The 
precise physiological role of eHSP72 is not yet fully understood, but is thought to 
play a crucial role in immunological function by initiating the secretion of pro-
inflammatory cytokines (Tsan and Gao, 2004) and acting as a ‘danger signal’ to the 
immune system, thus offering increased cellular protection (Campisi et al., 2003; 
Fleshner and Johnson, 2005). 
 
The eHsp72 response to thermal (Lovell et al., 2007; Gibson et al., 2014) and 
exercise stress (Lancaster et al., 2004; Walsh et al., 2001) is documented, with their 
combination (exercise heat-stress) increasing the response further compared to 
exercise alone (Whitham et al., 2007). Core temperature (Tcore) of >38.5°C has 
demonstrated a strong relationship to the magnitude of eHsp72 response (Gibson et 
al., 2014; Périard et al., 2012; Ruell et al., 2006). Endurance events also appear to 
initiate a substantial increase in eHsp72 expression due to their prolonged duration. 
Fehrenbach et al. (2005) demonstrated that a marathon run (260 ± 39 min at 
approximately 65% V O) led to a > 2.5-fold increase in eHSP72 in comparison to 
a 120 min run at 60% V O, suggesting that exercise duration likely played a key 
role in the differential eHSP72 response seen. This was supported by Suzuki et al. 
(2006), whereby eHSP72 expression following an ironman triathlon (average finish 
time 9 h 59 min ± 0 h 34 min) increased 22-fold from baseline [compared to > 2.5-
fold increase post marathon (Fehrenbach et al., 2005)], which was said to be as a 
function of exercise duration. The greater increase in eHSP72 following the 
ultramarathon (Suzuki et al., 2006), in comparison with the marathon run 
(Fehrenbach et al., 2005), supports the role of exercise duration as a key function of 
eHsp72/eHSP72 induction. Exercise duration (Suzuki et al., 2006) therefore appears 
to be, alongside Tcore >38.5°C (Gibson et al., 2014), a main function of increased 
eHsp72 release. This is interesting given the increasing popularity of physically 
demanding ultra-endurance events (Knechtle et al., 2011); which are defined as races 
with distances >42 km or durations >6 hours [h; (Zaryski and Smith, 2005)]. Notable 
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events include the Jungle Marathon [>250 km over 6 days (d) within Brazilian 
rainforest], the Badwater Ultra (>200 km, Death Valley USA) and the Marathon des 
Sables [MDS (~250 km over 6 d within Sahara Desert)]. The extreme exercise heat-
stress encountered by participants within such events can include temperatures 
>45°C (MDS) and relative humidity’s (RH) >80% (Jungle Marathon); evidently 
placing competitors at an increased risk of developing EHI related 
pathophysiologies. 
 
Endurance exercise, especially in the heat, is often accompanied by gastrointestinal 
(GI) discomfort and is estimated at 30-90% prevalence within distance runners 
(Brouns and Beckers, 1993), with the possibility of mild to moderate 
symptomatology, including nausea, stomach cramps and bloating, and serious 
symptoms, such as haemorrhagic gastritis, hematochezia and ischemic bowel (Strid 
and Simrén, 2005). Exercise-induced GI discomfort and dysfunction is multi-
factorial relative to aetiology, but is often primarily attributed to exercise heat-stress 
mediated hyperthermia per se and splanchnic hypoperfusion (Lambert, 2004; Moses, 
2005), as blood is shunted away from the viscera and redirected to the heart, skin and 
skeletal muscles (Qamar and Read, 1987). Subsequent epithelial tight junction 
damage can occur, culminating in GI barrier dysfunction (Van Wijck et al., 2011), 
allowing paracellular movement of lipopolysaccharides (LPS; endotoxins) into the 
bloodstream which can lead to endotoxemia (Bouchama and Knochel, 2002; Zuhl et 
al., 2012). Yeh et al. (2013) noted a 54% increase in LPS concentration from 
baseline following 60 min running (70% V O, 33°C, 50% RH.), with Gill et al. 
(2015) demonstrating that 75% of participants in a 24 h continuous ultramarathon 
had at least one severe GI symptom which co-presented with a ~37% increase in 
circulating endotoxin concentration upon event completion compared to baseline. 
These increases (Gill et al., 2015; Yeh et al., 2013) are of concern as increased 
circulating levels of endotoxins can lead to fever, dizziness and GI distress, and may 
potentially result in sepsis and multi-organ damage (Van Leeuwen et al., 1994). The 
aforementioned symptoms of endotoxemia are associated with decrements in overall 
performance (Brock-Utne et al., 1988; Pfeiffer et al., 2012), and it is therefore 
plausible to suggest that this will negate optimal recovery between demanding 
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endurance based exercise heat-stress bouts with limited recovery time (< 12 h), such 
as those experienced during the MDS. 
 
Given that both endurance exercise (Fehrenbach et al., 2005) and elevated Tcore 
>38.5°C (Gibson et al., 2014) are reportedly key functions for the increased eHsp72 
concentration during exercise, it is extremely likely that undertaking an 
ultramarathon in extreme environmental conditions (e.g. >45°C) would initiate a 
significant eHsp72 response. In addition, increased circulating LPS, a common 
response to endurance performance (Brock-Utne et al., 1988; Ng et al., 2008), 
reportedly stimulates Hsp72 synthesis, in order to restore cellular homeostasis (Chan 
et al., 2004; Hauser et al., 1996; Lau et al., 2000) and thus an amalgamation of the 
aforementioned stressors is expected to increase the expression of eHsp72 during 
ultramarathon performance. The subsequent and potentially protective physiological 
effect of increased eHsp72 expression on endotoxemia has been less commonly 
investigated. However, a modest increase in temperature (from 37°C to 41°C) has 
been shown by Dokladny et al. (2006) to increase eHSP70 expression in vitro, 
leading to a subsequent protective effect on heat-induced tight junction barrier 
disturbance; suggesting elevated eHSP72 may reduce GI barrier permeability and 
thus theoretically could reduce endotoxemia [this is important given that 
endotoxemia has been shown to decrement physical performance (Pfeiffer et al., 
2012)]. However, research in this area is sparse, and further investigation is required 
to fully understand the effect of increased circulating LPS (and the possible 
protective influence of increased eHSP70/72 concentrations) in human exercise 
models per se, particularly for exercise models like the MDS.  
 
Evidently, methods to reduce GI permeability and the subsequent risk of 
endotoxemia during long duration exercise are required to ensure optimal 
performance and recovery (including between bouts) is achieved. Nutritional 
interventions have been investigated, such as bovine colostrum ingestion 
(Marchbank et al., 2011; Morrison et al., 2014), glutamine supplementation 
(Lambert et al., 2001; Zuhl et al., 2015), fluid replacement (Lambert et al., 2001), 
and ascorbic acid supplementation (Ashton et al., 2003), but have shown equivocal 
results. Probiotics [defined as ‘living microorganisms which upon ingestion in 
certain numbers exert health benefits beyond general nutrition’ (Guarner and 
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Schaafsma, 1998)] have recently gained interest due to the potential benefits on the 
gut and gut barrier function. Specifically, probiotic supplementation has been shown 
to enhance defence against infection via increased strength of tight junction proteins, 
maintenance of cellular polarization and mucosal homeostasis (Mengheri, 2008; 
Otczyk and Cripps, 2010; Sherman et al., 2009). Kekkonen et al. (2007) 
demonstrated a reduction in GI-symptoms in marathon runners following chronic 
probiotic supplementation, however the data regarding the effect in ultra-endurance 
events is not currently available. Given such events can last >24 h and have limited 
recovery time between demanding exercise heat-stress bouts (<12 h), competitors 
are likely to experience elevated eHsp72 expression (Fehrenbach et al., 2005; 
Périard et al., 2012), and are at increased risk of GI discomfort during performance 
(Gill et al., 2015). As a result, methods to attenuate detrimental GI-related side 
effects are required to optimize performance in ultra-endurance based exercise (i.e. 
during the MDS). This research therefore aims to investigate the effect of 12 weeks 
(wk) of chronic probiotic supplementation prior to an ultra-endurance event, and its 
effects on LPS translocation, GI discomfort and any subsequent eHsp72 response. 
 
CHAPTER 2: Literature Review  
 
2.1 Heat stress and thermoregulation 
 
Humans are homeothermic and attempt to maintain an optimal Tcore of ~37°C 
through mechanisms of heat loss and heat gain (Benzinger, 1969; González-Alonso, 
2012). Heat exchange occurs at all times in humans to ensure that an optimal Tcore is 
maintained. The heat balance equation (Figure 2.1), derived from the first law of 
thermodynamics, models the rate of heat storage utilizing the four major 
mechanisms of heat exchange: conduction (Ċ), convection (K̇), radiation (Ṙ) and 
evaporation (Ė), and is as follows (Cheung, 2009): 
 
Ṡ = Ṁ ± Ẇk ± Ṙ ± Ċ ± K̇ - Ė (W.m-2) 
Figure 2.1. The heat balance equation (Cheung et al., 2000). 
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Ṁ refers to metabolic heat production, and Ẇk refers to the external work performed 
by the individual. A positive value for Ṡ represents elevated body heat storage, 
which could eventually lead to hyperthermia (Cheung et al., 2000).  
 
Thermal homeostasis is required in order to ensure that optimal molecular, cellular, 
physical and cognitive function is maintained (Nakamura and Morrison, 2008; 
Bandelow et al., 2010; Parker et al., 2013; Sawka and Montain, 2000). During 
exercise, especially in extreme environments (e.g. MDS), Tcore increases (González-
Alonso et al., 1999; Nielsen et al., 1997) and thus physiological methods to promote 
heat loss are required (Cheung et al., 2000). Thermosensitive neurons in the 
preoptic-anterior hypothalamus detect increases in Tcore, and receive afferent sensory 
input from thermoreceptors throughout the body [including the spinal cord, internal 
organs and the skin (Wendt et al., 2007)]. This allows the hypothalamus to initiate 
the most appropriate thermoregulatory response to the thermal stress, in an attempt 
to regulate Tcore at the optimal ~ 37°C (Benzinger, 1969).  
 
When exposed to extreme conditions, such as hot or cold, the human body will 
exhibit physiological changes in order to regulate temperature at the optimal level 
(Cheung, 2009). One key physiological change that occurs is redistribution of blood 
flow to reduce skin temperature, or sweating to increase evaporative heat loss 
(Sawka et al., 2011). Elevated Tcore leads to heat transfer from the core to the skin, to 
allow the dissipation of heat to the environment via vasodilation and the 
aforementioned mechanisms of heat loss (Sawka et al., 2011). Approximately 50-
80% of the heat flow in the tissue is carried in or out by the blood flow, and it is said 
that human Tcore would rise by 12°C in an hour if heat loss via blood flow did not 
occur (Acharya et al., 2014). Skin blood flow can increase by ~ 6-8 L/min via 
thermoregulatory vasodilation as a result of hyperthermia (Charkoudian, 2003). This 
elevation requires the redistribution of blood to the skin from other areas exhibiting a 
lower demand for blood flow during performance, such as the splanchnic region 
(Clausen, 1977).  
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2.2 Exercise in the heat  
 
Exercise in the heat exerts severe levels of physiological stress upon the body, due to 
the increased cardiovascular and thermoregulatory demands (González-Alonso et al., 
2008). Maintenance of thermoregulatory homeostasis is more complex during 
exercise heat-stress; due to the increase in metabolic heat production (principally 
from the active skeletal muscle) combined with the impairment of heat loss 
mechanisms, resulting in elevated Tcore [see Figure 2.1 (Gleeson, 1998; Nybo, 
2008)]. This rise in Tcore, coupled with the aforementioned (section 2.1) competition 
for limited blood flow (Tan and Lee, 2015), may ultimately impair endurance 
performance (Nybo et al., 2014), and can lead to exercise heat-stress induced illness, 
such as hyperthermia, GI discomfort and endotoxemia (Brock-Utne et al., 1988). 
 
A plethora of research is available to demonstrate the detrimental effects of heat 
exposure on exercise performance across a variety of exercise types (Parkin et al., 
1999; Wingo et al., 2005), particularly prolonged duration endurance exercise, due 
to extended exposure to extreme heat (Ely et al., 2007; Peiffer and Abbiss, 2011). 
An increased Tcore combined with elevated exogenous heat stress can lead to 
deteriorations in performance (Nybo et al., 2014), and several studies (Galloway and 
Maughan, 1997; Lorenzo et al., 2010; Tatterson et al., 2000; Tucker et al., 2004) 
have demonstrated the impact of exogenous heat on performance, indicating a 
reduction in exercise capacity in hot conditions. Endurance running imposes great 
levels of physiological and mechanical stress upon the body due to the ‘whole body’ 
nature of the exercise (Dawson et al., 1985), and as a result, performance capacity is 
significantly impaired. It is possible that this decline in performance is related to the 
increased risk of heat related illness during exercise-heat stress. Such illness, 
including hyperthermia (Nybo et al., 2014) and gut related discomfort and 
dysfunction (Lambert, 2004) may induce further illness, such as endotoxemia 
(Brock-Utne et al., 1988), and can result in both central and peripheral fatigue 
(Cheung and Sleivert, 2004; Supinski et al., 2000), and thus subsequently impair 
performance and recovery [including between consecutive (i.e. < 12 h) exercise 
bouts]. Additionally, athletes undertaking ultra-endurance exercise are at an 
increased risk of heat-related illness due to the prolonged exposure to unfavourable 
conditions, which can exceed 24 h (Gill et al., 2015).  
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2.2.1 The Marathon des Sables 
 
Ultra-endurance events are becoming increasingly popular (Knechtle et al., 2011). 
The MDS, a footrace covering > 250 km across the Sahara Desert over 7 d, is an 
ultramarathon often referred to as ‘the toughest footrace on earth’. Competitors are 
required to carry all of their own equipment and food, must consume at least 1,500 
kcal per day, and are rationed to ~ 9 L of water per day. Undertaking ultra-endurance 
events in extreme environments can place individuals at extreme risk of heat-related 
illness, such as hyperthermia, and may also increase the risk of gut related 
discomfort, which could consequently impair performance (Edler et al., 2014; 
Sawka, 2004). These side effects could prove severely detrimental in events, such as 
the MDS, where within race recovery between stages is vital. The mechanistic 
physiological responses to target in an attempt to reduce the risk of such illness 
(including increased HSP72 concentration, amongst others) will be discussed in 
further detail in section 2.3. 
 
2.3 Specific responses to exercise heat-stress  
 
2.3.1 The molecular response: Extracellular heat shock proteins 
 
As detailed in section 2.2, exercise heat-stress places the human body under severe 
levels of stress (González-Alonso et al., 2008; Nybo, 2008). Protective physiological 
responses, acute and chronic in nature, are required to reduce the risk posed by 
exercise and exercise heat-stress, and to prevent potential cellular and tissue damage 
(Morimoto and Santoro, 1998). Heat shock proteins (also frequently termed stress 
proteins) are a family of highly conserved proteins produced in response to 
conditions of extreme stress (Heck et al., 2012; Whitley et al., 1999). It is highly 
accepted that iHsp72 is found in the majority of the body’s cells, and is upregulated 
in response to cellular and organismic stressors (Hartl, 1996). However, research 
into the role of eHsp72 has only recently gained interest. In a clinical setting, 
Pockley et al. (2002) demonstrated that individuals suffering with disease states such 
as atherosclerosis (Pockley et al., 2003), hypertension (Pockley et al., 2002), and 
renal disease (Wright et al., 2000) had chronically higher basal eHsp72 levels in 
comparison to healthy age-matched controls. Following these findings, Walsh et al. 
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(2001) and Febbraio et al. (2002a) reported a rapid increase in the concentration of 
eHsp72 after exposure to acute stressors in human cells in the absence of clinical 
disease states. As a result, these studies were the first to recognise eHsp72 release as 
a feature of the normal stress response, with the increased eHsp72 concentration 
suggested to activate the immune response (Moseley, 2000). Acute stressors, 
including psychological stress (Fleshner et al., 2004), trauma (Pittet et al., 2002), 
exercise-stress (Lancaster et al., 2004) and heat stress (Lovell et al., 2007) induce an 
increase in eHsp72 concentration in both human and animal models. 
 
The exact mechanism of exercise-induced eHsp72 release is currently not fully 
understood, however two mechanisms have been suggested, dependent on the mode, 
intensity and/or duration of exercise: i) through cellular necrosis [muscle damage 
(Suzuki et al., 2006) or haemolysis (Whitham and Fortes, 2006)]; or ii) through an 
active exocytosis mechanism (Lancaster and Febbraio, 2005; Mambula et al., 2007). 
Cell lysis or death can lead to the passive release of HSP72 into the extracellular 
environment (Basu et al., 2000; Fleshner and Johnson, 2005). HSP72 is released into 
the extracellular milieu following cell/tissue necrosis, causing the protein content of 
the cell to ‘spill’ into the surrounding space (Whitham and Fortes, 2008). Exercise 
can cause damage to the sarcolemma, which reflects necrosis, and may contribute to 
the exercise-induced increase in eHSP72 (Fehrenbach et al., 2005). However a direct 
correlation between eHsp72 and markers of muscle damage is yet to be reported, 
thus these mechanisms remain speculative (Whitham and Fortes, 2008). The release 
of hormones from the pituitary gland via the hypothalamic-pituitary-adrenal (HPA) 
axis, or sympatho-adrenalmedullary (SAM) axis, is activated by a stress response 
caused following the exposure to stressful exercise-induced stimuli, such as 
increased oxidative stress (Fischer et al., 2006) and Tcore (Ruell et al., 2006). The 
origin of eHsp72 is currently unclear, but is thought to involve lipid rafts, exosomes 
and lysosomes (Lancaster and Febbraio, 2005). Figure 2.2, from Whitham and Fortes 
(2008), demonstrates a proposed model for in vivo human exercise-induced release 
of eHsp72. 
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Figure 2.2.  Model for the exercise-induced release of eHsp72 [Adapted from Whitham and Fortes (2008)].
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2.3.1.2 Exercise and the heat shock response  
 
As stated in section 2.3.1, exercise has been shown to trigger an increase in eHSP72 
concentration. Exercise causes a disturbance to cellular homeostasis and places the 
body under increased stress, instigating a subsequent need for increased eHSP72 
concentration for cellular protection (Kregel, 2002). Moseley (1997) stated that the 
heat strain imposed upon the body during heat stress is reduced via enhanced HSP72 
synthesis. A plethora of evidence is available to support this theory, and 
demonstrates the increase in eHSP72/eHsp72 caused by exercise stress (see Table 
2.1). 
 
Endurance exercise has been shown to induce a significant increase in eHsp72 
concentration. In temperate conditions, Walsh et al. (2001) were the first to 
demonstrate an exercise-induced release of eHsp72, whereby an increase from 0.13 
± 0.10 ng/mL at rest to 1.02 ± 0.41 ng/mL immediately post-exercise was found 
following 60 min treadmill running at 70% V O . Lancaster et al. (2004) 
supported these findings, showing an average eHsp72 increase of ~1.00 ± 0.38 
ng/mL from pre- to post-exercise following 180 min cycling at 60% V O . 
Additonal research (as detailed in Table 2.1) has reinforced this evidence across a 
variety of exercise modalities, durations and intensties.  
 
Fehrenbach et al. (2005) demonstrated a duration- and intensity- dependent role for 
exercise-induced eHSP72 release, whereby prolonged duration exercise, a marathon 
run (260 ± 39 min) at 60% V O , led to a greater eHSP72 concentration 
immediately post-exercise (16.3 ± 12.1 ng/ml) in comparison with a shorter duration 
run (120 min) at the same intesity (4.2 ± 2.2 ng/ml). The significantly higher 
eHSP72 concentration following the marathon run suggests a key role for exercise 
duration in eHSP72 production. Furthermore, exercise in extreme environmental 
conditions has been shown to initiate a larger eHsp72 response (Table 2.1). Gibson 
et al. (2014) clearly demonstrated this effect through 90 min cycling at 50% V O 
in three experimental conditions. Following exercise in extreme heat (40°C, 37% 
RH), eHsp72 concentration was increased by 172.4% from baseline, whereas the 
same exercise at 30.2°C, 51% RH led to an eHsp72 increase of just 25.7%. It was 
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suggested that these changes were modulated by large, rapid changes in Tcore, with 
the greatest increase displayed during exercise at 40°C, therefore demonstrating a 
significant role of exogenous and endogenous heat stress on eHsp72 concentration. It 
was suggested that Tcore of >38.5°C was a key threshold for the increase in eHsp72 
concentration (Amorim et al., 2008). Périard et al. (2012) reinforced this initial data, 
and supported the notion of a Tcore threshold for eHsp72 release (Gibson et al., 
2014), whereby Tcore >38.5°C, when combined with exercise stress, was shown as 
the most potent stimuli for increased eHsp72 concentration, and indicated the 
importance of exercise intensity and duration as modulators of eHsp72 release. A 
significant correlation was found between eHsp72 and attained Tcore following 
cycling to exhaustion at 60% V O in 40°C, 50% RH; and rate of increase in Tcore 
at 75% V O in the same conditions. 
 
2.3.1.3 Ultra-endurance and the heat shock response 
 
Evidently, exercise duration is a key modulator of eHsp72 release (Amorim et al., 
2008; Febbraio et al., 2002b; Marshall et al., 2006), and thus ultra-endurance events, 
defined as lasting >6 h (Zaryski and Smith, 2005), are likely to induce a significant 
increase in eHsp72 concentration. Of the limited research available regarding ultra-
endurance events, evidence thus far has demonstrated a significant post-exercise 
increase in eHSP70 concentration. An ironman triathlon, consisting of a 3.8 km 
swim and a 180 km cycle followed by a 42.2 km run in moderate ambient 
temperatures (23.3°C ± 1.9°C), with an average finish time of 9 h 59 min ± 0 h 34 
min, led to a 22-fold increase in plasma eHSP70 from pre- to post-race (Suzuki et 
al., 2006). Gomez-Merino et al. (2006) compared the eHSP70 response to two ultra-
endurance events: a long distance triathlon (4 km swim, 120 km cycle, 30 km run) in 
12 trained male triathletes, and a 100 km run in 12 trained male ultramarathoners, in 
similar ambient temperatures, (24.1°C and 25.5°C in the triathlon and run, 
respectively). Interestingly, eHSP70 concentration following the 100 km run (16.74 
± 0.64 ng/mL) was 173% higher than eHSP70 concentration following the long 
distance triathlon (6.13 ± 0.61 ng/mL), despite no signfiicant difference in exercise 
duration between events. Gomez-Merino et al. (2006) postulated that the greater 
disruption of cellular homeostasis caused by the 100 km run elicited a greater 
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eHSP70 response, which was thought to be upregulated as a method of cellular 
protection. This is an interesting finding suggesting that ultra-endurance running (as 
opposed to swimming or cycling) may lead to the greatest change in eHSP70 
concentration, due to the increased degree of whole body stress (Dawson et al., 
1985; Rehrer et al., 1989), potentially leading to increased membrane 
disturbance/damage (Oktedalen et al., 1992) and thus an increase in eHsp72 
concentration through the aforementioned (section 2.4.1) necrosis-related release 
mechanism (Suzuki et al., 2006). The two events completed in this study were 
undertaken in warm environments [peak: 23°C (Suzuki et al., 2006) and 24.1°C 
(Gomez-Merino et al., 2006)], thus it is highly likely that undertaking ultra-
endurance running in hot conditions (>30°C), such as those experienced in the MDS, 
will initiate an even greater eHSP70 response, due to the combined effects of 
exercise and heat stress.  
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Table 2.1. An overview of studies investigating the effect of exercise and exercise heat-stress on eHsp72 concentration. 
Author (year) Subjects Study design Temperature Blood sampling  Effect on eHSP72 (mean ± SD)  
 
Exercise stress only 
 
     
Walsh et al. (2001) 6 subjects, male 
n=5, female n=1 
60 minutes treadmill 
running (70% V O) 
20°C, 40% RH Intravenous blood sample 
from forearm. [Pre-, 30 min 
(during) and Immediately-, 
2h- and 8h- post-exercise] 
↑ Serum Hsp72:  
Rest: 0.13 ± 0.10 ng/mL 
30 min (during): 0.87 ± 0.24 
ng/mL 
Immediately post: 1.02 ± 0.41 
ng/mL  
 
Febbraio et al. 
(2002b) 
7 healthy, active 
males (19-33 
years) 
2.5h 2-legged leg extensor 
exercise (40% Wmax).  
Glycogen depletion trial 24h 
pre-exercise.  
Main trial: 4-5h (until 
exhaustion) at 40%Wmax. 
Comparing HSP in depleted 
leg (DL) vs control leg (CL) 
 
Not stated Femoral artery and vein in 
right leg, femoral vein in left 
leg cannulated. Blood 
sample taken at rest, 1h hour 
intervals during exercise.  
DL: ↑ HSP72  ~2 –fold 
immediately after exercise 
 
CL: ↔ HSP72 
Lancaster et al. 
(2004) 
6 healthy 
endurance 
trained males 
180 minutes cycling (60% 
V O). Consumed ~250ml 
CHO solution every 15 min.  
21°C ± 1°C Catheter in internal jugular 
and radial artery, samples 
taken pre- and immediately 
post-exercise for measures 
of cerebral Hsp72.  
↑ Arterial serum Hsp72 in 4 of the 
6 subjects by ~1.00 ± 0.38 ng/ml 
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Ruell et al. (2006) Male runners 
with (EHI, n = 
22) and without 
(CON, n=7) 
previous history 
of exertional 
heat illness. 
14km “Surf to City” run, 
Sydney. 
21°C, 33% RH Venous blood samples 
within 10 min of completion 
(CON) or immediately upon 
admission to medical facility 
(EHI).  
↑ Plasma eHsp72 in severe EHI vs 
mild EHI immediately post-
exercise.  
Whitham et al. 
(2006) 
10 healthy, male, 
endurance 
trained cyclists 
90 min cycling (74 ± 1% 
V O) following 
consumption of 6 ml/kg 
body mass 1) Caffeine or 2) 
Placebo.  
 
21.1 ± 0.8°C, 52 ± 
5% RH 
Venous blood samples for 
plasma HSP72:  
Pre-supplement, pre-, 
immediately post-, 1h post- 
exercise.  
↑ HSP72 in both groups compared 
to baseline.  
↑ HSP72 greater in caffeine 
compared with placebo group.  
 
Exercise heat-
stress 
 
     
Marshall et al. 
(2006) 
7 non-heat 
acclimated males 
2 consecutive days cycling 
at 42.5% V O  
38°C, 60% RH  Venous blood sample from 
antecubital vein, pre-, 
immediately post- and 22h 
post- exercise using 
cannulation 
 
During exercise: ↑ eHSP72 
~1.26ng/ml.  
2 hours of passive heating (38°C):  
↔ eHSP72.  
Whitham et al. 
(2007) 
11 moderately 
trained males 
2h immersion/ deep water 
running (58% V O). 
Exercise induced heat 
(EIH), Clamped exercise 
Water temp: 
EIH: 35.3 ± 0.9°C 
CLex: 23.5 ± 
0.9°C 
Venous blood samples for 
plasma eHSP72: pre-, 
immediately post- and 
60min post- exercise.  
All trials: significantly ↑ eHSP72. 
Exercise heat-stress = greatest ↑ 
eHSP72. 
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(CLex) Passive heat (PH) 
control (CON).  
 
PH: 38.5 ± 0.2°C 
CON: 35.3 ± 
0.2°C 
 
Amorim et al. 
(2008) 
9 heat-
acclimated 
subjects.  
Male, n=7 
Female n=2  
Repeated measures, 
counterbalanced design. 
Heat acclimation- 10d 
walking/running at 56% 
V O for 100min (42°C, 
30% RH). 3d post-
acclimation: 2x heat stress 
trials at a low (LS) or high 
(HS) rate of heat storage. 
 
42°C, 30% RH Venous blood sample from 
antecubital vein pre- and 
post-exercise. 
↑ eHsp72 from pre- to post- 
exercise in both conditions.  
Périard et al. (2012) 16 males Cycle to exhaustion (60% vs 
75% V O) 
40°C, 50% RH Venous blood samples: rest, 
10min, 30min, exhaustion, 
and 24h post. 
↑ eHsp72 in both conditions 
following exercise to exhaustion  
Gibson et al. (2014) 10 healthy males 90min cycling (50% 
V O) Repeated 
measures: 
1) 20°C, 63% RH (TEMP) 
2) 30.2°C, 51% RH (HOT) 
3) 40°C, 37% RH (VHOT) 
 
1) 20°C, 63% RH 
(TEMP) 
2) 30.2°C, 51% 
RH (HOT) 
3) 40°C, 37% RH 
(VHOT) 
 
Venous blood samples for 
plasma eHsp72 taken pre-, 
immediately post- and 24h 
post- exercise. 
VHOT: ↑ eHsp72 +172.4%  
 
HOT: ↑ eHsp72 + 25.7% (p > 
0.05) 
TEMP: ↓ eHsp72 - 1.9% (p > 0.05) 
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Ruell et al. (2014) 14 male runners 
with (n=7) and 
without (n=7) 
previous history 
of exertional 
heat illness  
60 min treadmill run (72% 
V O).  
30°C, 40% RH Cannula inserted into 
antecubital vein and blood 
samples taken every 10 min 
for plasma eHSP72 
↑ Plasma eHSP72: 
CON: 1.18±0.14 ng/ml (rest), 4.56 
± 0.63 ng/ml (60 min) 
EHI: 0.86 ± 0.08 ng/ml (rest), 4.04 
± 0.45 ng/ml (60 min).  
 
Taylor et al. (in 
press) 
6 males  Randomised double-blind 
crossover design. High 
intensity running protocol” 
20 x 10s runs (23.0 ± 1.8 
km/h-1). 7 d effective 
microorganism –x 
supplementation or 7 d 
placebo followed by 1 HOT 
and 1 TEMP.  
TEMP: 20.4°C 
HOT: 34.7°C 
Venous blood sample taken 
from antecubital fossa 
↑ Plasma eHsp72 pre- to post-
exercise. ↑ eHsp72 was moderated 
by temperature.  
TEMP: ↑ eHsp72 + 0.8 ng/ml, 
HOT: ↑ eHsp72 +1.5ng/ml (↑ 
418%).  
Ultra-endurance 
exercise 
     
Gomez-Merino et 
al. (2006) 
12 male 
triathletes vs 12 
male 
ultramarathoners  
Triathlon (4 km swim, 120 
km cycle, 30 km run) vs 100 
km run 
Triathlon: peak 
24.1°C 
Ultramarathon: 
peak 25.5°C 
Venous blood sample ↑ eHSP72 following triathlon 
(6.13 ± 61ng/ml-1) and 
ultramarathon (16.74 ± 4.34 ng/ml-
1). 173% greater ↑ in runners vs 
triathletes.  
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↑ = increase; ↓ = decrease; ↔ = no change. 
Suzuki et al. (2006) 9 male triathletes Ironman Triathlon (3.8km 
swim, 180km cycle, 42.2km 
run) 
23.3 ± 1.9°C 60 ± 
14% RH 
Venous blood sample, 2 
days pre-race, within 30min 
post-race 
↑ Plasma HSP70 2200% from 
baseline to post-race 
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2.3.2 The gastrointestinal response 
 
At rest 20% of the cardiac output is received by the splanchnic organs, but only 10-
20% of the available oxygen (O2) is consumed (Rowell et al., 1964). During 
exercise, O2 demand is significantly increased, resulting in the redistribution of blood 
to the organs, skin and working muscles and away from the intestines (Qamar and 
Read, 1987). Research has demonstrated significant reductions in gut blood flow 
during exercise. Cycling at 70% V O for 60 min led to a reduction in splanchnic 
blood flow of between 50% (Peters et al., 2001) and 80% (Rehrer et al., 2001), with 
reductions as big as 87% seen following exercise at 97% V O (Rowell et al., 
1964). Reduced splanchnic blood flow can lead to gut ischemia, with a reduction in 
small intestinal blood supply of > 50% shown to induce detectable mucosal tissue 
injury (Bulkley et al., 1985), which can consequently lead to GI related discomfort 
and dysfunction. 
 
Damage to the epithelial tight junctions and intestinal walls as a result of gut 
ischemia (and other mechanisms) can increase intestinal permeability and result in 
GI barrier dysfunction (Van Wijck et al., 2011). This increase in permeability can 
allow undesirable translocation of LPS from the gut into the systemic circulation 
(Berkes et al., 2003), which can lead to symptoms including nausea, fever, dizziness 
and possible endotoxemia, should LPS concentration increase to > 5 pg/ml 
(Schippers et al., 2008). Figure 2.3 [adapted from Lambert (2004)] displays the flow 
of events leading to GI barrier dysfunction and endotoxemia as a result of exercise 
heat-stress. 
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Figure 2.3. The flow of events leading to GI barrier dysfunction, and the possible 
consequences of such disruption [Adapted from Lambert (2004)]. 
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2.3.2.1 Exercise and the gastrointestinal system 
 
During exercise, GI discomfort can lead to impaired endurance performance (Rehrer 
et al., 1989). Riddoch and Trinick (1988) demonstrated that 83% of 471 marathon 
runners suffered from GI disturbances during or immediately after running, and 29% 
of runners felt that their performance had been adversely affected by these 
symptoms. During exercise in the heat, Tcore increases at a faster rate, which leads to 
an increased demand for skin blood flow for heat dissipation and therefore a 
subsequent reduction in splanchnic blood flow, consequently placing the individual 
at a greater risk of exercise-induced endotoxemia and GI discomfort (Otte et al., 
2001; van Wijck et al., 2012). 
 
Following 60 min running at 70% V O in 33°C, 50% RH, LPS concentration 
increased by 54%, whereas no significant increase in LPS concentration was shown 
following the same exercise in 25°C, 60% RH (Yeh et al., 2013), indicating a role of 
heat stress upon LPS translocation. Furthermore, Ng et al. (2008) reported a 31.6% 
increase in LPS concentration following a 21 km road race in warm and humid 
conditions (exact temperatures not reported). Whilst only 4 of the 30 runners studied 
by Ng et al. (2008) met the criteria for mild endotoxemia (LPS concentration > 5 
pg/ml), it is important to recognise the significant increase in LPS concentration 
caused by exercise heat-stress. GI discomfort data was not reported in these studies 
(Ng et al., 2008; Yeh et al., 2013), however elevated LPS concentration has 
previously been shown to relate to GI discomfort (Bosenberg et al., 1988; Brock-
Utne et al., 1988), and thus future research should investigate this relationship 
further, particularly under conditions of extreme heat stress. 
 
Moreover, ultra-endurance events also reportedly lead to significant levels of GI 
discomfort; Stuempfle et al. (2013) reported nausea, abdominal cramps, diarrhoea 
and vomiting from 9 of 15 runners following a 161 km ultramarathon. Whilst LPS 
was not recorded and thus details of GI damage cannot be elucidated, it is clear that 
GI discomfort was a common occurrence. Jeukendrup et al. (2000) also 
demonstrated the GI response to ultra-endurance exercise following an ironman 
triathlon (3.8 km swim, 185 km cycle, 42.2 km run) in conditions peaking at 32.1°C. 
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Of 29 athletes, 93% reported symptoms of GI discomfort, with 7% forced to 
abandon the race due to severe GI distress (vomiting and diarrhoea). In addition, 
elevated LPS concentration was detected in 68% of athletes, and although only mild 
endotoxemia (5 – 15 pg/ml) was observed, this demonstrated the effect of ultra-
endurance exercise on the GI system. The impact of ultra-endurance exercise has 
previously been established by Brock-Utne et al. (1988), whereby 80% of 89 runners 
experienced endotoxemia (LPS > 100 pg/ml) following an 89.4 km race, and 2% 
experienced lethal concentrations of LPS (> 1000 pg/ml). It is suggested that 
exercise modality may influence the degree of discomfort; as the increased stress 
caused by the up and down motion of running may induce a greater degree of GI 
damage (Brouns and Beckers, 1993). Brock-Utne et al. (1988) also demonstrated 
that 80.6% of runners with elevated plasma LPS concentration reported GI 
symptoms including nausea, vomiting and/or diarrhoea, whereas only 17.7% of 
runners with low LPS concentration reported these symptoms. Although less 
research has been conducted regarding the GI response to ultra-endurance exercise, 
existing knowledge indicates the possibility of a key relationship between LPS 
concentration and GI discomfort during ultra-endurance running performance, 
particularly in hot environments.  
 
As stated in section 2.2.3, the MDS is classed as one of the toughest ultramarathons 
in the world, consisting of 7 d consecutive exercise, with the longest stage requiring 
competitors to cover ~ 80 km in 24 h, in the heat of the Sahara Desert (reaching up 
to 50°C). This substantial level of demand placed upon the human body will likely 
cause a significant increase in Tcore, leading to potential gut ischemia and subsequent 
LPS translocation and GI distress. However, research into the effect of the MDS 
upon GI discomfort has not yet been conducted, thus will be of great interest to 
practitioners to comprehend the damage that can occur during an ultramarathon in 
such extreme environmental conditions, and consider plausible interventions to 
offset this potentially serious medical condition. 
 
2.3.3 LPS and eHsp72 
 
The relationship between circulating LPS and eHsp72 is still incompletely 
understood. Animal studies have demonstrated a clear, protective effect of eHsp72 in 
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septic animals in vivo (Lin et al., 2010; Wischmeyer et al., 2001), through a 
reduction in pro-inflammatory cytokine release (Singleton and Wischmeyer, 2007) 
and enhanced cell survival (Zhao et al., 2012). A review of 41 animal studies by 
Briassoulis et al. (2014) demonstrated a 95.8% level of protection by both intra- and 
extra-cellular Hsp72 against sepsis. The induction of eHsp72 demonstrated a strong 
protective effect, and led to enhanced survival in all septic animal models. 
 
However, the role of eHsp72 in response to elevated circulatory LPS concentration 
in humans is currently somewhat inconclusive. Selkirk et al. (2009) demonstrated a 
protective role of eHsp72, whereas McConnell et al. (2011) indicated a possible 
relation of eHsp72 to mortality and infection. Of 14 human studies analysed by 
Briassoulis et al. (2014), only 50% showed a protective eHsp72 response, and 14.3% 
demonstrated a non-protective eHsp72 response to sepsis. Tulapurkar et al. (2015) 
demonstrated that in vitro treatment with LPS for 6 h in human THP-1 cells 
stimulated eHsp70 release, which indicates a possible protective role of eHsp72 
against the stress induced by elevated LPS concentration. However, further research 
into this relationship is required to develop a greater understanding regarding the 
role of eHsp72 against this increased level of stress.  
 
It is plausible that an ‘inverted U’ stress response, in line with the classic Hans Selye 
(1946) General Adaptation Syndrome (GAS), could be seen in response to changes 
in LPS concentration. This theory detailed a three-phase response to stress in humans 
(Figure 2.4), whereby a protective effect is demonstrated in response to an 
appropriate amount of stress, however too much stress can be severely detrimental: i) 
phase 1, the Alarm phase, provides the initial response to stress, also referred to as 
the ‘fight or flight response’, ii) phase 2, the Resistance phase, demonstrates the 
body’s reaction/adaptation to the imposed stressors, whereby resources are focused 
to resist the elevated stress, and iii) phase 3, the Exhaustion phase, which can occur 
if the stress has continued for a prolonged duration, presents a loss in the body’s 
ability to resist the stress, and can ultimately be severely detrimental, possibly even 
causing death. It could be postulated that the changes in eHsp72 concentration in 
response to the initial increase in LPS translocation can offer a protective effect and 
may aid the reduction/prevention of heat-related illness associated with elevated LPS 
concentration. However, if the increase in LPS concentration is too large, the eHsp72 
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response may be insufficient and therefore unable to offer continuous protection 
against the imposed stress.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. The General Adaptation Syndrome [Adapted from Selye (1946)]. 
 
The protective role of eHsp72 against elevated LPS concentration may occur through 
i) enhanced endotoxin tolerance (Aneja et al., 2006), and ii) enhanced epithelial 
barrier function (Moseley et al., 1994; Musch et al., 1999). Firstly, endotoxin 
tolerance, a reduced capacity of the host to respond to LPS activation following 
exposure to relatively low LPS concentration (Fan and Cook, 2004), can have a 
protective effect and increase resistance to tissue injuries and mortality in models 
including infected thermal injury (He et al., 1992), and hepatic ischemia/reperfusion 
(Heemann et al., 2000). It has been shown that eHsp72 reduces the increase in pro-
inflammatory cytokine release following LPS exposure, and subsequently leads to an 
increased level of tolerance against LPS (Aneja et al., 2006). Aneja et al. (2006) 
stated that a higher eHsp72 concentration can increase tolerance to LPS, which can 
in turn reduce the risk of heat-related illness. Furthermore, it was demonstrated that 
monocytes treated with eHsp70 showed a greater reduction in the release of pro-
inflammatory cytokines in response to LPS stimulation in comparison to non-treated 
cells (Aneja et al., 2006). Cultured monocytes were treated with 0.03 µg/ml eHSP70, 
1. Alarm phase  
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3. Exhaustion phase  
Death Homeostasis 
 25
incubated for 18 h, then washed and stimulated with LPS. These in vitro findings 
demonstrate a protective role of eHsp70 against LPS through an enhanced level of 
tolerance. A greater eHsp72 concentration coincided with greater LPS tolerance, and 
as exercise heat-stress has been previously shown to induce a significant increase in 
eHsp72 concentration (Amorim et al., 2008; Gibson et al., 2014; Whitham et al., 
2007), it is possible that trained individuals undertaking such exercise will portray a 
greater degree of tolerance. Secondly, it is possible that increased eHsp72 
concentration may serve to reduce LPS translocation by enhancing intestinal 
epithelial barrier function (Moseley et al., 1994; Musch et al., 1999). As stated in 
section 2.3.1, damage to the intestinal epithelial barrier can subsequently lead to a 
greater degree of LPS translocation into the circulatory system (Berkes et al., 2003; 
Van Wijck et al., 2011). Musch et al. (1999) demonstrated a protective role of 
eHsp72 upon epithelial barrier function against oxidant-induced stress, and further 
research has previously demonstrated that GI barrier protection is commonly linked 
to the increased eHsp72 concentration (Tao et al., 2006; Wischmeyer et al., 1997; 
Wischmeyer et al., 2001). These findings indicate the importance of increased 
eHsp72 concentration on GI barrier function, which is essential for the reduction of 
LPS translocation (Lambert, 2004). Further research is required to further understand 
the relationship between eHsp72 and LPS concentration, and should focus on 
increasing the concentration of eHsp72 to protect against the intestinal damage that 
could lead to substantial LPS translocation. In addition, it is important to note that 
the aforementioned in vitro studies are less directly comparable to the changes that 
occur in plasma eHsp72, and thus whilst these changes give a clear indication of the 
potential effect that may occur, it is still essential to undertake further research in 
vivo, in order to fully understand the effect of LPS concentration upon the eHsp72 
response. 
 
2.4 Strategies to offset the endotoxemia response 
 
As demonstrated in section 2.4.1, GI distress caused by increased intestinal 
permeability can commonly occur during ultra-endurance exercise, particularly in 
the heat (Brock-Utne et al., 1988; Jeukendrup et al., 2000). Potential nutritional 
interventions have been explored, focusing on maintaining GI barrier integrity to 
prevent (though likely limit) LPS translocation during exercise heat-stress. 
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Bovine colostrum, the first milk produced after calving, is rich in nutrients and 
bioactive components (Playford et al., 2000), and although supplementation has been 
shown to improve GI barrier integrity following heat-stress in rats (Prosser et al., 
2004), findings regarding the effect in humans have been equivocal. Marchbank et 
al. (2011) found an ~80% reduction in the rise in exercise-induced permeability 
following colostrum supplementation when compared to a placebo trial, whereas 
Morrison et al. (2014) found no physiological or performance benefits following 7 d 
supplementation. Ascorbic acid supplementation has been shown to abolish the 
increase in LPS both pre- and post-exercise (cycling to volitional exhaustion), 
however this alteration did not appear to influence exercise performance and lacks 
external validity to running based ultra-endurance events. Carbohydrate ingestion 
has demonstrated positive preventative effects (Jeukendrup, 2014; Oliveira et al., 
2014) but has also been shown to induce GI discomfort (de Oliveira and Burini, 
2011). Currently it is difficult to identify the most effective in vivo method to reduce 
GI permeability and discomfort during exercise, and indicates the importance of 
robust empirically informed methods to prevent gut related negative effects during 
exercise heat-stress. 
 
2.4.1 Probiotic supplementation 
 
Dietary probiotic supplementation has been shown to benefit individuals suffering 
from diseases affecting the GI tract, due to their proposed positive effects upon the 
gut and gut barrier integrity. Probiotic supplementation in animal models has 
demonstrated an improvement in gut integrity (Zareie et al., 2006), and research into 
human clinical populations has often exhibited positive health effects of 
supplementation. Reduction in GI discomfort and GI side effects in individuals 
suffering from illnesses such as chronic fatigue syndrome (Lakhan and Kirchgessner, 
2010), diarrhoea (Brigidi et al., 2001; Chapman et al., 2011), irritable bowel disease 
(Jonkers and Stockbrügger, 2003) and lactose intolerance (de Vrese et al., 2001), 
have been found following probiotic supplementation. 
 
There are a number of mechanisms by which probiotics exert these beneficial 
actions: i) through inhibiting the overgrowth of pathogenic bacteria (Vanderhoof et 
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al., 1998), ii) by increasing the secretion of mucin (Otte and Podolsky, 2004), iii) by 
competing with pathogenic bacteria for binding sites on mucins and/or epithelial 
cells (Mack et al., 2003), iv) through enhancing the stability of tight junctions 
between epithelial cells (Seth et al., 2008) and v) through the activation of heat 
shock factor-1 (HSF-1), an activator responsible for the transcription of heat shock 
genes, leading to elevated Hsp72 concentration (Zuhl et al., 2014). All of the above 
mechanisms can offer a greater understanding regarding the role of probiotic 
supplementation on GI health.  
 
As stated in section 2.3.2, strenuous exercise can lead to increased epithelial tight 
junction permeability, which can ultimately allow increased LPS leakage into the 
circulation (Berkes et al., 2003), leading to GI discomfort. Research investigating the 
role of probiotics during athletic performance has received little attention, however it 
is sensible to predict that by utilising probiotic supplementation to strengthen tight 
junction stability (Seth et al., 2008), LPS translocation and GI discomfort during 
performance may be reduced. 
 
Kekkonen et al. (2007) demonstrated a reduction in the duration of GI symptoms 
suffered by athletes during training and following a marathon after a three-month 
probiotic supplementation programme. This reduction in length of GI symptoms 
could be extremely beneficial for recovery between consecutive exercise bouts, 
which may be particularly important for multi-day events, such as the MDS, that 
require athletes to perform on successive days. In addition, Lamprecht et al. (2012) 
demonstrated the beneficial effects of a 14 wk supplementation period [1010 colony 
forming units (CFU) per day] on intestinal permeability in athletes at rest, which led 
to a 20% decrease in Zonulin concentration. Zonulin, a protein released from the 
liver and intestinal epithelial cells, is a main modulator of intercellular tight junctions 
(Fasano, 2011), of which increased concentration relates to changes in tight junction 
competency and GI permeability. The 14 wk supplementation programme 
implemented by Lamprecht et al. (2012) was evidently sufficient to initiate a 
reduction in resting GI permeability, however post-exercise GI permeability was not 
recorded, and thus conclusions regarding the effect of probiotic supplementation 
upon exercise-induced GI damage cannot be determined. Further research is 
therefore required to investigate the effect of probiotic supplementation on exercise-
 28
induced GI damage, potentially through the implementation of longer duration 
exercise in hotter conditions.  
 
Shing et al. (2014) demonstrated an improvement in running performance by 16% in 
a time to fatigue run at 80% ventilatory threshold (35°C, 40% RH) after 4 wk of 
probiotic supplementation in comparison with a placebo. Exercise induced a 
significant increase in LPS concentration from baseline in both conditions, however 
the pre- and post- exercise values were lower [although not statistically significant – 
Cohen’s effect size: pre: 0.70, post: 1.24 (Cohen, 1988)] in the probiotic compared to 
the placebo group. These findings indicated that probiotics may perhaps exert small 
to large effects on GI integrity and LPS translocation that may result in 
improvements upon exercise performance in the heat.  
 
These studies (Kekkonen et al., 2007; Lamprecht et al., 2012; Shing et al., 2014) 
demonstrate the role of probiotic supplementation on the GI response to exercise 
through exerting beneficial effects upon the intestinal tight junctions. A further 
mechanism of interest is the induction of eHsp72 to protect against GI damage. 
Research has shown that probiotic supplementation may enhance eHsp72 
upregulation (Petrof et al., 2004; Tao et al., 2006). Novel research from Tao et al. 
(2006) investigated the effect of the probiotic strain Lactobacillus GG on Hsp72 
expression in intestinal epithelial cells in vitro. Hsp72 has been shown to play a key 
cytoprotective role against damage to preserve epithelial tight junction and barrier 
function (Musch et al., 1999), and thus it was hypothesised that a key mechanism of 
probiotic action is the ability to induce cytoprotective Hsps, such as Hsp72. 
Lactoballicus GG exposure led to the induction of eHsp72, which indicated that the 
cytoprotective role of probiotics may occur through increased eHsp72 concentration. 
Tao et al. (2006) also discovered a reduction/loss of most protective effects when 
Hsp72 was abolished from the cells, indicating the importance of this increased 
concentration for protection against epithelial cell injury. 
 
In addition to probiotics, the amino acid glutamine (GLn), thought to be the primary 
fuel source for intestinal cells (Irvin and Heuberger, 2015), plays a key role in 
intestinal function, structure and metabolism (Akobeng et al., 2000). Similar to the 
effects of probiotics, oral GLn supplementation has been shown to enhance intestinal 
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barrier function by decreasing intestinal permeability in both animal (dos Santos et 
al., 2010) and human (Zuhl et al., 2014) models, with a key protective mechanism 
thought to be through the induction of Hsp72 (Wischmeyer, 2002; Zuhl et al., 2015). 
Wischmeyer et al. (2001) demonstrated that a single dose of intravenous GLn caused 
a rapid and significant increase in Hsp72 expression in a rat model. Additionally, 
endotoxin-treated animals given GLn exhibited a substantial increase in tissue Hsp 
expression and a decrease in end-organ damage. These findings indicated GLn to be 
a clinically viable enhancer of Hsp expression. Zuhl et al. (2015) supported these 
findings and demonstrated that oral GLn supplementation attenuated an exercise-
induced rise in intestinal permeability, and subsequently increased HSP70 induction. 
Furthermore, Zuhl et al. (2014) found that the exercise-induced increase in intestinal 
permeability caused by 60 min running at 70% V O was completely ameliorated 
in the GLn trial. This protective effect was thought to be associated with HSF-1 
activation, which leads to protein stabilisation and a reduction in intestinal 
permeability, and thus a subsequent increase in HSP70 expression. 
 
Evidently, both probiotic and GLn supplementation have demonstrated protective 
roles against GI discomfort, damage and dysfunction. Research investigating the 
relationship between probiotic supplementation, gut health and the eHsp72 response 
in humans has received little attention, and the effect during ultra-endurance exercise 
is unknown. The combination of exercise-induced heat-stress and exercise-induced 
gut damage may lead to an increase in the concentration of cytoprotective eHsp72; 
which may lead to a greater level of protection, and thus reduce the risk of GI related 
illness. In addition, the added benefits of GLn combined with probiotic 
supplementation could lead to greater improvements in gut barrier integrity and a 
reduction in intestinal permeability through increased Hsp72 concentration.  
 
2.5 Overall summary 
 
It is evident that endurance and ultra-endurance running in the heat can often induce 
an increase in GI permeability and subsequent LPS translocation, leading to severe 
discomfort for the individual (Berkes et al., 2003; Brock-Utne et al., 1988; 
Jeukendrup et al., 2000). The resultant level of stress from such exercise can cause 
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an increase in the concentration of eHsp72 as a method of cytoprotection (Lee et al., 
2006; Moseley, 1997). This elevated eHsp72 concentration may reduce GI barrier 
damage (Musch et al., 1999), however, the role of eHsp72 in response to exercise-
induced endotoxemia requires further investigation.  
 
In order to enhance protection against such side effects, nutritional interventions can 
perhaps be employed. Both probiotic and glutamine supplementation have been 
shown to offer beneficial effects through the strengthening of tight junctions between 
epithelial cells (Seth et al., 2008) and via increased eHsp72 concentration (Zuhl et 
al., 2014). However, the effect of these interventions upon the GI and heat shock 
responses to ultramarathon performance has not yet been investigated, and thus 
further research is required, which could provide novel knowledge and 
understanding indicating a method by which stress can be reduced during 
ultramarathon events.  
 
2.6 Aims and hypothesis  
 
To investigate the effects of 12 wk probiotic supplementation on LPS translocation 
and the resulting eHsp72 response following a multi-day ultra-endurance event in 
extreme heat. 
 
1. Probiotic (PRO) and probiotic + glutamine (PGLn) supplementation will 
increase eHsp72 concentration from baseline to pre-race in comparison to 
CON. 
2. Post-race, eHsp72 concentration will be significantly increased in all groups. 
3. PRO and PGLn will demonstrate a significantly greater eHsp72 
concentration in comparison to CON. 
4. LPS concentration following the MDS will show the greatest increase in the 
CON group compared to PRO and PGLn. 
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2.7 Novelty of Research Project  
 
To reiterate the novelty of this research project, it has been shown that previous 
research has investigated the eHsp72 response to ultra-endurance events, and has 
demonstrated the role of PRO upon LPS concentration. However, this study is the 
first to collect data from a large sample following the MDS, a race that takes place in 
a logistically challenging location and environment. Additionally, this novel study 
has, for the first time, investigated the role of PRO and PGLn upon both eHsp72 and 
LPS concentration over a 12 wk supplementation period, following the MDS, and 7 
d post-race to investigate the duration of the effect. This study therefore aims to 
address the gap in the knowledge, whereby understanding the effect of PRO upon 
the eHsp72 and LPS response during ultra-endurance events could have a significant 
impact upon an individual and the GI response to such exercise.  
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CHAPTER 3: Experimental Chapter - Chronic Probiotic 
Supplementation and its Effects on eHsp72 and LPS 
Concentration Following a Desert-Based Ultramarathon 
 
3.1 Introduction 
 
Exercise in extreme environmental conditions can place severe physiological stress 
on the human body (Nielsen and Nybo, 2003; Walsh and Whitham, 2006; Nybo, 
2008). Such stress (see section 2.3.1) can elicit an increase in eHsp72 concentration 
(Marshall et al., 2006; Whitham et al., 2007; Périard et al., 2012; Ruell et al., 2014), 
in order to offer a protective role through preparing the immune system for the 
associated exercise-induced stressors (Johnson and Fleshner, 2006). 
 
Prolonged exercise in such environments can result in an increased incidence of GI 
dysfunction and discomfort, including symptoms of nausea, stomach cramps and 
bloating (Jeukendrup et al., 2000; Hoffman and Fogard, 2011); with the risk of 
further serious conditions, including haemorrhagic gastritis, hematochezia and 
ischemic bowel (Strid and Simrén, 2005). Such GI dysfunction can be attributed to 
the leakage of LPS from the GI mucosa into the systemic circulation (Berkes et al., 
2003; Yeh et al., 2013), often detrimentally affecting performance and ‘overall’ 
health of the individual or athlete (Ter Steege and Kolkman, 2012).  
 
To acquiesce such exercise-induced GI damage, nutritional interventions have been 
trialled to improve overall gut health (Jeukendrup, 2014; Morrison et al., 2014; 
Oliveira et al., 2014). Clinical probiotic supplementation has been shown to improve 
gut health and offer protection/treatment relative to various diseases, including 
inflammatory bowel disease (Shadnoush et al., 2015), Crohn’s disease (Guslandi et 
al., 2000; Gupta et al., 2000) and ulcerative colitis (Cui et al., 2004; Matthes et al., 
2010). Initial research suggests potential beneficial health effects, particularly 
attributed to gut health, of probiotic supplementation in trained individuals [see 
section 2.4.1; (Kekkonen et al., 2007; Gleeson et al., 2011; Pyne et al., 2015)]. 
Supplementation of both PRO (Tao et al., 2006; Petrof et al., 2004) and GLn 
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(Wischmeyer, 2002) have demonstrated the ability to induce eHsp72, which plays a 
crucial indirect role in maintaining gut epithelial barrier integrity (Amorim and 
Moseley, 2010). Thus, the enhancement in GI health induced by PRO or a 
combination of PRO and GLn (PGLn) supplementation (mechanisms described in 
section 2.4.1), alongside the potential role of probiotics upon eHsp72 induction 
could, at least hypothetically, reduce the detrimental effects of LPS translocation in 
athletes during ultra-endurance exercise  
 
3.1.1 Aims and Hypothesis 
 
The aim of this study is to investigate the effect of chronic (12 wk) probiotic 
supplementation on LPS translocation, GI discomfort and the eHsp72 response to 
ultra endurance running in extreme heat.  
 
The experimental hypotheses were as follows:  
 
1. PRO and PGLn supplementation will increase eHsp72 concentration from 
baseline to pre-race in comparison to CON. 
2. Post-race eHsp72 concentration will be significantly increased in all groups. 
3. PRO and PGLn will demonstrate a significantly greater eHsp72 
concentration in comparison to CON. 
4. LPS concentration following the MDS will show the greatest increase in the 
CON group compared to PRO and PGLn. 
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3.2 Methods 
 
3.2.1 Participants 
 
Thirty-two competitors taking part in the MDS 2015 (6 female, age 41; range 23-53 
years, height 1.75 ± 0.08 m, body mass 76.89 ± 2.04 kg) were recruited for this 
study. Prior to commencement of the study, participants were provided with a 
detailed information sheet (Appendix A), outlining the purpose, procedures and risks 
of the study, and were made aware that they were free to withdraw from the study at 
any time. All participants provided written informed consent (Appendix B), were 
deemed healthy and able to take part (Appendix C), and all participants verbally 
confirmed that they were not currently undertaking any probiotic or glutamine 
supplementation regime. All procedures were approved by the Anglia Ruskin 
University Ethics Committee, and conformed to the Declaration of Helsinki.  
 
3.2.2 Probiotic supplementation 
 
Following a randomised, independent measures design, using simple randomization, 
participants were assigned to one of three experimental conditionsgraos: probiotic 
capsules (PRO), probiotic + glutamine powder (PGLn), or control (CON). 
Participants were instructed as to the requirements for their specific group and were 
required to follow these instructions to ensure compliance to the study intervention; 
daily adherence to the intervention was self-reported at 100% for all groups. Due to 
the nature of the study, blinding of groups was not possible, however, the PGLn 
group were unaware of the addition of GLn to their probiotic supplement.  
 
PRO: were required to consume one capsule (BioAcidophiilus Forte, UK) per day 
for the duration of the 12 wk intervention period; capsules contained Lactoballicus 
acidophilus (100 mg), Fructooligosaccharides (60 mg), Bifidobacterium bifidum 
(22.2 mg) and Bifidobacterium lactis providing a total of 30 billion viable 
proprietary organisms (see Appendix D for full ingredients).  
 
PGLn: were required to consume 5 g powder (GI Complex, UK) per day, mixed well 
in water or food. The key probiotic strains in the PGLn were Lactobacillus 
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acidophilus (40.5 mg), Lactobacillus salivarius (25 mg), Bifidobacterium bifidum 
(3.5 mg) and Bifidobacterium lactis, providing a total of 10 billion viable organisms; 
each 5 g dose also contained 0.9 g L-Glutamine (see Appendix E for full details).  
 
CON: were required to continue with their normal diet, and were to refrain from any 
substantial changes and supplementation regime. 
 
All supplements were donated to the research team by BioCare, UK, in order for use 
in this research study. Dosages were selected based on the recommended dosage 
from BioCare, UK, in order to investigate an ecologically valid supplementation 
regime.  
 
3.2.3 Study overview 
 
Data was collected at four time points across the duration of the study, which 
consisted of three laboratory visits and one field-based data collection point. Data 
was collected on two occasions prior to the race: i) 12 wk (visit 1; baseline) and ii) 7 
d (visit 2; pre-race) prior to departure for the MDS, and two further occasions post-
race: iii) 6 - 8 h post-race (post-race data collection) and iv) 7 d post-race (visit 3).  
 
Visits 1 and 2: Participants arrived at the environmentally controlled laboratory 
(18°C, 35% RH) in a fasted state (minimum 4 h fasted) with consumption of alcohol 
and caffeine, and undertaking of physical activity 24 h prior to each visit forbidden, 
with apparent adherence confirmed at 100% for all participants. Upon arrival, 
participants rested in a semi supine position for measures of resting heart rate [(HR), 
Polar, FS1, UK], followed by a venous blood sample via venepuncture from the 
antecubital fossa for analysis of eHsp72 and LPS (as detailed further in section 
3.2.7). Body composition was subsequently measured via skinfolds (section 3.2.5), 
followed by the completion of a V O  test (section 3.2.6; see Figure 3.1 for 
experimental schematic). 
 
Post-race data collection: Upon completion of the race (full race details provided in 
section 3.2.4), participants boarded coaches and were taken from the Desert back to 
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the city of Ouarzazate, for post-race data collection. A team of experimenters 
measured body composition and collected post-race venous blood samples (in line 
with procedures outlined in sections 3.2.5 and 3.2.7, respectively); this data 
collection took place 6 - 8 h post-race completion. 
 
Visit 3: Participants attended the sport science laboratories 7 d post-race, which 
involved the same experimental procedures as visits 1 and 2, but excluded the 
completion of a V O test. 
 
3.2.4 The Marathon des Sables 
 
The MDS 2015 took place from 5th – 11th April, and covered a total distance of 
249.4 km across the Sahara Desert, Morocco (average temperature ~ 38°C), over 7 
days. Each stage started at 0900 h and consisted of the following distances 
completed in one day unless indicated otherwise: stage 1 (36.2 km), 2 (31.1 km), 3 
(36.7 km), 4 (91.7 km; two day stage), 5 (42.2 km) and 6 (11.5 km). The MDS 
required competitors to be self sufficient, meaning they were to carry their own food 
(minimum 1500 kcal per day), equipment, and sleeping materials for the duration of 
the race. Water was rationed to ~ 9.0 – 10.5 L/day per competitor, dependent on the 
distance of the stage. At the end of each stage, participants were required to 
complete a GI symptoms questionnaire [(Appendix F) adapted by Roberts, J.D. and 
Roberts, M.G. (2013) from Lipski (1998)] independently without direct 
experimenter oversight, detailing any general and/or specific GI discomfort 
experienced throughout the entire stage. Participants were required to complete this 
questionnaire within 2 h of stage completion; adherence was reported at 100% across 
the duration of the race. 
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Figure 3.1. Experimental schematic outlining the experimental study design and data collection time points.  
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Data collection point 2: Lab visit 2: Pre-race   
Data collection point 3: Field testing: Post-race 
MDS 2015 
Data collection point 4: Lab visit 3: 7 days post race  
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3.2.5 Body composition 
  
A seven-site skinfold measurement using skinfold calipers (Harpenden, Cranlea, 
UK) was conducted to calculate body fat percentage using the appropriate American 
College of Sports Medicine (ACSM) equation (ACSM, 2013). Two measurements 
were taken from each site by the same qualified experimenter for all participants, in 
order to to obtain a mean value and increase reliability of results.  
 
3.2.6   
 
During visits 1 and 2, participants were required to undertake a graded exercise test 
to maximal exhaustion on a motorized treadmill (Pulsar, HP Cosmos, UK) for the 
measurement of V O. Participants were fitted with a HR monitor (Polar, FS1, 
UK) and suitably sized metalyser mask (Cortex, UK). After a 5 min self-paced warm 
up, participants exercised to volitional exhaustion following a standardized 
incremental protocol from the British Association of Sport and Exercise Sciences 
[BASES; (Winter et al., 2006)]. Starting speed was selected based on the 
individuals’ preferred running speed. Speed was increased by 1 km/h-1 every 2 min, 
after 4 stages (8 min) speed remained constant and treadmill incline increased by 1% 
every 2 min until volitional exhaustion (Winter et al., 2006). Online breath-by-breath 
analysis (Metalyser 3B, Cortex, UK) was used to determine V O, and measures of 
HR and ratings of perceived exertion (RPE) were recorded every 2 min to be used as 
secondary criteria. The V O was considered as the highest V O obtained in any 
10 s period, and in line with end point criteria guidelines of the ACSM; which 
required participants to meet a plateau in V O, plus 2 of the 3 following criteria: a 
failure of HR to increase with increasing exercise intensity, respiratory exchange 
ratio (RER) of > 1.15, and RPE > 17 (ACSM, 2013).  
 
3.2.7 Blood collection and analysis 
 
Venous blood samples were collected at all four data collection time points. A 12 ml 
whole blood sample was drawn from the antecubital fossa via venepuncture (Safety 
blood collection set and holder, Vacuette®, Greiner Bio-One, UK), directly into 
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three separate Vacuette® tubes (Vacuette® Grenier Bio-One, UK) treated with K3 
Ethylenediaminetetraacetic acid (EDTA) coagulant (3 x 4 mL tubes). Whole blood 
samples were centrifuged (EBA 200, Hettich, Germany) at 3000 rpm for 10 min for 
plasma separation, which was then pipetted into 1.5 ml Eppendorf tubes (Fisher 
Scientific, UK) and stored at - 80°C until analysed for eHsp72 and LPS using a 
commercially available high-sensitivity enzyme-linked immunosorbent assay 
(ELISA) kits. 
 
3.2.7.1 Extracellular heat shock protein 72 
 
A commercially available ELISA kit (HSP70 high sensitivity ELISA kit, Enzo Life 
Sciences, Exeter, UK) was used to determine eHsp72 concentration in plasma 
samples (see appendix G for raw plate layouts and data). Determination of eHsp72 
was performed according to the manufacturers guidelines. Briefly, incubation of the 
96-well kit was performed on an incubital shaker (Heidolph Titramax 1000, Fischer 
Scientific, UK) at 500 rpm, and read by a plate reader (VICTOR™ X, Perkin Elmer, 
UK) using absorption at 450 nm. A graph for linearity between known samples 
concentration and optical density was used to ensure accuracy of sample data 
(Appendix H). Translation of raw plate reader data to eHsp72 units (nm/ml-1) was 
performed using a linear trendline and equation (see Appendix H). To eliminate 
intra-assay variation, samples were measured in duplicate where possible. Intra-
assay variability was 9.93%; which was in line with previous work in the field: 
Campisi et al. (2003): < 10%; Gibson et al. (2014): 10.5%; Périard et al. (2012): 5%; 
Walsh et al. (2001): < 10%; Whitham et al. (2006): 6.3%.  
 
3.2.7.2 Lipopolysaccharides 
 
Changes in circulatory LPS concentration were determined using a commercially 
available ELISA kit (Pierce™ LAL Chromogenic Endotoxin Quantitation Kit, 
ThermoFisher Scientific, UK) following the manufacturers guidelines (see appendix 
G for raw plate layouts and data). Two additional dilutions were applied to add two 
extra calibration points at the lower end of the calibration curve, to increase accuracy 
of readings at the lower end of the curve. Briefly, incubation of the 96-well kit was 
performed on an incubital shaker (Heidolph Titramax 1000, Fischer Scientific, UK) 
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at 500 rpm, and read by a plate reader (VICTOR™ X, Perkin Elmer, UK) using 
absorption at 405 nm. Endotoxin concentration was determined using a standard 
curve plotting the blank-corrected absorbance for each standard versus its 
concentration in EU/mL (Appendix I). The co-efficient of determination was > 0.98 
for all assays. To eliminate intra-assay variation, samples were measured in duplicate 
where possible. Intra-assay variability was 3.7%; previous LPS research has failed to 
report this data, and thus, based on the guidelines of Reed et al. (2002), an intra-
assay variability of < 20% is commonly accepted as reliable. 
 
3.2.8 Statistical analysis 
 
All data were analysed using IBM SPSS Statistics for Macintosh, Version 21 (IBM 
Corp, Armonk, NY). Quantile-quantile (Q-Q) plots were used to assess the normality 
of distribution for all variables. All data is presented as mean ± standard deviation 
(SD) when normally distributed, for data that violated the normality assumption the 
median and range is reported, statistical significance was accepted at p < 0.05. In 
line with previous Hsp72 research (Morton et al., 2006; 2007; 2008; Tuttle et al., 
2015) linear mixed model analysis was used to identify the effect of time, group, and 
group x time on the dependent variables. Data were analysed for differences between 
genders, where a difference was found between genders, females and males data are 
reported separately, where no difference was found between males and females, data 
were collapsed and analysed as a whole in line with the principal of parsimony. In 
accordance with previous literature, eHsp72 (Gibson et al., 2014; Morton et al., 
2007; Peart et al., 2011; Sandström et al., 2008; Suzuki et al., 2006; Taylor et al., 
2010a; Taylor et al., 2010b) and LPS (Costa et al., 2014; Gill et al., 2015; Olesen et 
al., 2015) concentrations were expressed as a percentage change from baseline, to 
account for high individual variance in baseline values and responses.  
 
3.2.9 Research team 
 
As stated, this research was conducted in collaboration with the Sport and Exercise 
Science Research Group at Anglia Ruskin University, Cambridge. I (Hannah 
Marshall), was present at three of the four data collection blocks, and aided with all 
lab-based data collection. Due to funding issues, it was not possible to attend data 
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collection point 3 (field testing 6-8 h post-race, Morocco). Two members of the 
research team, [Craig Sucking (Ph.D. student, Anglia Ruskin University) and 
myself], ran the ELISAs for analysis of eHps2 concentration, whilst LPS ELISAs 
were ran separately at Anglia Ruskin University, with raw data being sent to myself 
for analysis.  
 
3.3 Results 
 
3.3.1 Group characteristics 
 
Anthropometrical data is displayed in Table 3.1. Linear mixed model analysis 
revealed that there was a significant effect of time on V O (F2,29 = 17.537, p < 
0.001). Pre-race mean V O was significantly greater than baseline mean V O 
by 3.92 ml.kg.min-1 (95% CI: 2.003 – 5.845 ml.kg.min-1). There was no significant 
effect of group (F2,27 = 0.963, p = 0.393) or group x time (F2,27 = 0.077, p = 0.926) on 
V O. Additionally, there was a significant effect of time on body mass, with a 
significant reduction observed from 76.89 ± 2.04 kg to 75.27 ± 2.04 kg from 
baseline to pre-race, respectively (F1,28 = 18.712, p < 0.001). There was no 
significant group (F2,29 = 1.417, p = 0.259) or group x time (F2,28 = 2.828, p = 0.076) 
effect on body mass. There was a significant effect of gender on body fat % (F1,238 = 
49.803, p < 0.001), which was shown to be significantly lower in male participants 
(18.43 ± 0.36%) compared to females [(24.77 ± 0.83%); 95% CI: 4.574 – 8.117%]. 
A significant gender x group effect (F2,238 = 13.842, p < 0.001) displayed that 
females in the CON group (31.25 ± 1.06%) had a greater body fat % than females in 
the PRO (21.26 ± 1.83%) and PGLn (21.63 ± 1.29%) groups, no significant 
difference was shown between groups for male participants. There was no 
significant effect of gender x time (F3,238 = 0.037, p = 0.990) or gender x group x 
time (F6,238 = 0.673, p = 0.671) on body fat %. There was no significant effect of 
group (F2,31 = 0.294, p = 0.747), time (F1,31 = 0.438, p = 0.513) or group x time (F2,31 
= 0.070, p = 0.932) on HR. 
 
Two participants (both from the CON group) were disqualified from the race due to 
failing to complete a stage in the required cut-off time. Linear mixed model analysis 
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demonstrated a significant effect of group on overall MDS finishing time (F2,65 = 
4.147, p = 0.020). Sidak post-hoc tests demonstrated that the CON group completed 
the race in a significantly slower time (3043 ± 151 min) in comparison to PRO (2437 
± 164 min, 95% CI: 59.936 – 1152.400 min). Furthermore, following the removal of 
the two disqualified participants, the Linear mixed model analysis was re-run to 
assess any difference in results, and demonstrated a significant effect of group on 
finishing time (F2,58 = 4.023, p = 0.023). Sidak post-hoc tests revealed similar results 
to the previous analysis, whereby the MDS finishing time of the CON group (3052 ± 
181 min) was significantly slower than PRO (2249 ± 242 min, 95% CI: 60.272 – 
1546.35 min). There was no significant difference between CON and PGLn (2534 ± 
183 min), or PRO and PGLn. There was no significant effect of gender (F1,58 = 
0.176, p = 0.676) or gender x group (F2,58 = 3.132, p > 0.05).  
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Table 3.1. Anthropometrical characteristics of age, height, mass, body fat percentage, and V O data (wk 1 and wk 12) are reported as means 
± SD. 
 
 
 
HR: Heart Rate; b.min-1: beats per minute; kg: kilograms; V O : maximal volume of oxygen consumption; ml.kg.min-1: millilitres per 
kilogram per minute. PRO: Probiotic; PGLn: Probiotic + Glutamine; CON: Control.  
  
 
 
  
 
  Baseline     Pre-race  
Group Age 
(years) 
Resting HR 
(b.min-1) 
Mass 
(kg) 
Body fat %   
(ml.kg.min-1) 
 Resting HR 
(b.min-1) 
Mass (kg) Body fat %   
(ml.kg.min-1) 
PRO 38 ± 8 52 ± 8 78.87 ± 6.93 20.32 ± 3.99 56.42 ± 8.26  51 ± 5 77.49 ± 6.52 18.76 ± 2.73 59.40 ± 6.33 
PGLn 40 ± 8 55 ± 10 71.34 ± 12.92 19.74 ± 4.54 56.50 ± 5.95  55 ± 10 70.09 ± 12.31 19.07 ± 4.14 59.25 ± 6.92 
CON 42 ± 9 54 ± 12 79.50 ± 14.07 22.72 ± 8.56 51.17 ± 12.68  54 ± 14 77.29 ± 12.92 22.80 ± 9.32  55.25 ± 11.96 
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3.3.2 eHsp72 
 
Figure 3.2 illustrates overall mean eHsp72 concentration for PRO, PGLn and CON 
at baseline, pre-race, post-race and 7 d post-race. Linear mixed model analysis 
revealed that there was a significant effect of time on overall mean eHsp72 
concentration (F3,88 = 162.698, p < 0.001). Overall mean eHsp72 concentration was 
significantly greater post-race by 124% (95% CI: 106.287 – 141.782%), 122% (95% 
CI: 103.927 – 139.781%) and 111% (95% CI: 93.373 – 130. 545%) compared to 
baseline, pre-race and 7 d post-race, respectively (raw values are displayed in Table 
3.2). There was no significant effect of group (F2,31 = 1.304, p = 0.286) or group x 
time (F6,88 = 0.662, p = 0.680) on eHsp72 concentration (Figure 3.3 shows overall 
individual responses, Figure 3.4 a-c shows individual eHsp72 responses within 
groups over time). There was no significant correlation between post-race eHsp72 
concentration and MDS finishing time (r = 0.002, p = 0.991).  
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Figure 3.2. Mean (± SD) eHsp72 response between groups, as a % change from 
baseline. #Denotes significantly greater eHsp72 concentration post-race compared to 
all other time points (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Overall individual eHsp72 response over time as a % change from 
baseline.  
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Figure 3.4 a-c. Individual eHsp72 responses within groups, as a % change from 
baseline. (a: PRO, b: PGLn, c: CON).  
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3.3.3 LPS Concentration   
 
A significant effect of time was observed for overall mean LPS concentration (F3,91 
= 5.668, p < 0.001). Pre-race LPS concentration was 31, 43 and 30% greater than 
baseline, post-race and 7 d post-race, respectively (see Figure 3.5 for overall group 
mean LPS concentration). There was no significant effect of group (F2,31 = 0.401, p = 
0.673) or group x time (F6,91 = 0.583, p = 0.743) on LPS concentration (Figure 3.6 
shows overall individual responses, Figure 3.7 a-c shows individual eHsp72 
responses within groups over time, and raw data is displayed in Table 3.2). There 
was no significant correlation between post-race LPS concentration and MDS 
finishing time (r = 0.114, p = 0.529).  
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Figure 3.5. Mean (± SD) LPS response between groups, as a % change from 
baseline. #Denotes significantly greater LPS concentration at pre-race compared to 
all other time points (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Overall individual LPS responses, as a % change from baseline. 
 
Ba
se
lin
e
Pr
e-
ra
ce
Po
st-
ra
ce
 
7 d
ay
s
 
po
st-
ra
ce
-100
-50
0
50
100
150
200
Time
LP
S 
c
o
n
c
e
n
tr
a
tio
n
 
%
 
c
ha
n
ge
 49
Ba
se
lin
e
Pr
e-
ra
ce
Po
st-
ra
ce
 
7 d
ay
s
 
po
st-
ra
ce
-100
-50
0
50
100
150
200
Time
LP
S 
c
o
n
c
e
n
tr
a
tio
n
 
%
 
c
ha
n
gec
-100
-50
0
50
100
150
200
LP
S 
c
o
n
c
e
n
tr
a
tio
n
 
%
 
c
ha
n
gea
-100
-50
0
50
100
150
200
LP
S 
c
o
n
c
e
n
tr
a
tio
n
 
%
 
c
ha
n
geb
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. a-c. Individual LPS response within groups, as a % change from 
baseline. (a: PRO, b: PGLn, c: CON). 
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3.3.4 eHsp72 and LPS 
 
A Pearson’s correlation was used to determine the relationship between overall mean 
eHsp72 and LPS concentration at each data collection time point. A significant 
correlation was found between variables pre-race (r2 = 0.428, p = 0.013), however 
no correlation was observed post-race (r2
 
= 0.122, p = 0.492) or 7 d post-race (r2 = 
0.24, p = 0.900).  
 
3.3.5 GI discomfort 
 
Mild GI discomfort, including symptoms such as belching and nausea, was reported 
by 64, 56, and 58% of participants in PRO, PGLn, and CON groups, respectively 
throughout the entire race. There was no significant difference (p > 0.05) in GI 
discomfort between groups.  
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Table 3.2. Mean (± SD) eHsp72 (ng.ml-1) and LPS (pg.ml-1, EU/ml-1) concentrations between at each data collection time point. 
 
Group Baseline Pre-race 6 hours post race 7 d post-race 
eHsp72 (ng.ml-1)     
CON 1.68 ± 1.65 1.82 ± 1.98 3.45 ± 3.35 2.05 ± 2.49 
PRO 1.20 ± 0.58 1.58 ± 0.87 2.77 ± 1.21 1.80 ± 1.27 
PGLn 1.77 ± 2.51 1.03 ± 0.45 2.20 ± 0.76 1.04 ± 0.41 
LPS (pg/ml -1)     
CON 13.45 ± 14.77 17.30 ± 18.86 9.07 ± 2.69 8.57 ± 2.84 
PRO 8.99 ± 3.77 12.47 ± 3.67 7.85 ± 5.58 8.90 ± 3.79 
PGLn 9.33 ± 4.63 9.98 ± 4.44 6.54 ± 3.11 11.71 ± 4.18 
LPS (EU/ml-1)     
CON 0.13 ± 0.14 0.17 ± 0.18 0.09 ± 0.03 0.08 ± 0.02 
PRO 0.09 ± 0.04 0.13 ± 0.04 0.07 ± 0.06 0.09 ± 0.04 
PGLn 0.09 ± 0.04 0.10 ± 0.04 0.07 ± 0.03 0.09 ± 0.04 
eHsp72: extracellular heat shock protein 72; LPS: Lipopolysaccharides; PRO: Probiotic; PGLn: Probiotic + Glutamine; CON: Control.
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3.4 Discussion 
 
3.4.1 Key findings 
 
The key findings from this study were as follows: firstly, PRO and PGLn 
supplementation had no significant effect on eHsp72 concentration from baseline to 
pre-race in all conditions (p > 0.05), thus hypothesis one must be rejected. In line 
with hypothesis two, eHsp72 concentration was significantly increased post-race 
compared to baseline and all other time points (pre-race, 7 d post-race) in all groups 
(p < 0.05); there was no significant effect of group post-race or at any other time 
point (p > 0.05) contrary to hypothesis three. No significant change was seen in LPS 
concentration from baseline and pre-race to post-race in all groups (p > 0.05), and 
thus hypothesis four is rejected.  
 
3.4.2 eHsp72 response  
 
In contrast to hypothesis one, eHsp72 was not significantly increased from baseline 
to pre-race in PRO or PGLn. This was unexpected, as previous research has 
suggested that a key mechanism behind the protective role of PRO (Petrof et al., 
2004; Tao et al., 2006) and GLn (Wischmeyer et al., 2001) is the elevated induction 
of eHsp72. Tao et al. (2006) stated that induction of eHsp72 following PRO 
treatment in vitro may be transcriptional in nature, and was shown to induce binding 
of HSF-1, a key activator responsible for transcription of heat shock genes [section 
2.4.1; (Zuhl et al., 2014)]; future related work should include measurement of HSF-1 
within their designs to provide mechanistic evidence aligned to this hypothesis. Tao 
et al. (2006) also stated that Hsp genes were the most dramatically upregulated genes 
in response to PRO treatment, which suggests the induction of eHsp72 to be a key 
mechanism behind the protective role of PRO supplementation, and stated that PRO 
exposure of as little as a few minutes was sufficient to initiate signals to the 
epithelial cells for Hsp induction. Based upon this evidence, the 12 wk 
supplementation period utilised in the present study far exceeds the 16 h of in vitro 
exposure implemented by Tao et al. (2006) and thus was hypothesised to induce a 
significant increase in eHsp72 concentration, however, this increase did not occur. 
The PRO and PGLn supplements utilised in this study were commercially available 
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products (see section 3.2.4 and Appendices D and E for details), and thus whilst this 
aids external validity to current practice, it is possible that additional ingredients 
included in the supplements could have influenced the outcome of the study 
(Maughan, 2005). The wide range of available probiotic strains and bacteria, and the 
lack of quality control of probiotics (Tuomola et al., 2001), make comparisons 
between probiotic supplementation studies difficult; therefore future research 
utilising similar experimental designs should develop a standardised and 
pharmacologically optimised PRO supplement strain (which may likely be 
hybridised). 
 
In addition, GLn, described as a potent enhancer of the heat shock response [eHsp72 
in particular (Wischmeyer, 2002)], has reportedly led to increased HSP70 expression 
in intestinal epithelial cells, leading to protection against oxidant and heat injury 
(Wischmeyer et al., 1997). Zuhl et al. (2014) demonstrated that 7 d GLn 
supplementation led to a significant increase (p < 0.05) in HSP70 concentration in 
intestinal cells in vitro and, interestingly, prevented exercise-induced GI 
permeability. Findings from Zuhl et al. (2014) also indicated an absence of the 
HSP70 response to heat stress without GLn, and thus demonstrated i) the key role of 
this amino acid on HSP70 induction, and ii) the role of HSP70 in cellular protection 
in intestinal cells. In contrast to previous literature, the present study has displayed 
unexpected findings; this may be attributable to the prescribed GLn dosage, which 
was perhaps insufficient to induce a significant eHsp72 response. Previous studies 
exhibiting an increase in eHsp72 following GLn supplementation have utilised 
dosages relative to each individual participant, for example Zuhl et al. (2014; 2015) 
implemented a dosage of 0.9 g/kg fat free mass per day for each participant, whereas 
the present study applied a standardised dose of 5 g/day PGLn for all participants, 
which contained only 0.9 g of GLn per dose. This therefore may have been an 
insufficient dosage to induce an eHsp72 response in the PGLn group similar to that 
seen in previous studies (Zuhl et al., 2014; 2015). 
  
Although no significant change in eHsp72 concentration was found from baseline to 
pre-race, a significant elevation in eHsp72 concentration was shown post-race. This 
is in accordance with previous literature (Gibson et al., 2014; Gomez-Merino et al., 
2006; Lancaster et al., 2004; Suzuki et al., 2006; Walsh et al., 2001), which has 
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demonstrated the significant impact of exercise, heat stress, and the combination of 
both stressors upon the heat shock response. These findings demonstrate that 
participation in the MDS imposed a substantial level of stress upon all participants, 
subsequently inducing an overall mean increase in eHsp72 concentration of 124% 
from baseline to post-race. Due to the novelty of data collected in the present study, 
direct comparisons to previous research are difficult, and to the author’s knowledge, 
only two previous studies have reported the eHsp72 response to ultra-endurance 
exercise performance (Gomez-Merino et al., 2006; Suzuki et al., 2006). These 
studies demonstrated an increased eHsp72 concentration of ~ 2200% (Suzuki et al., 
2006) and ~ 1674% (Gomez-Merino et al., 2006) following an ironman triathlon and 
100 km run, respectively. Evidently, the post-race increase of 124% from baseline in 
the present study was less substantial than those ascertained in these previous 
studies, however, it is clear to see that a significant level of stress has been imposed 
upon the participants, to trigger the observed increase in eHsp72 concentration. One 
possible explanation for this seemingly less substantial increase in post-race eHsp72 
concentration in the present study is the timing of post-race blood sample collection. 
Due to the logistical issues of conducting field based research at the MDS, post-race 
samples were collected 6 - 8 h post-race, whereas previous research has collected 
samples immediately upon exercise completion (Gomez-Merino et al., 2006; Suzuki 
et al., 2006). As shown in Figure 3.8, Fehrenbach et al. (2005) previously 
demonstrated a significant increase in post-exercise eHsp72 concentration in vivo, 
which was shown to decrease back to baseline levels within 24 h post-exercise. As 
indicated in Figure 3.8, data in the present study was likely collected during the 
return to baseline concentration phase, and therefore may not provide an accurate 
representation of the eHsp72 response to ultramarathon exercise in extreme heat. 
The findings of Fehrenbach et al. (2005) indicate the time-course of changes in 
eHsp72 concentration following exercise, which may aid understanding regarding 
the less substantial increase observed in the present study when compared to 
previous research (Gomez-Merino et al., 2006; Suzuki et al., 2006). It can therefore 
be postulated that if samples were collected immediately post-race in the present 
experimental design, a greater eHsp72 concentration in comparison to those 
collected at 6 – 8 h post-race may have been seen. 
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Figure 3.8. Changes of soluble HSP72 (at rest, 0 h, 0.5 h, 3 h, and 24 h after 
exercise) in the plasma of endurance athletes after exercise of different intensity and 
duration. MA= marathon, LR = long run, CR = continuous run, IT = interval training 
were compared. *Denotes significant differences between pre- and post-exercise 
data, p < 0.05 (Fehrenbach et al., 2005). 
 
In addition, it is possible that a habituation effect may have occurred due to the 
multi-day nature of the event. Following 7 consecutive days of exercise heat-stress in 
extreme environmental conditions, participants would likely begin to acclimate to 
the extreme conditions. Full heat acclimation has been indicated to require 5-10 days 
(Sawka et al., 2011), thus by the 7th consecutive day of exercise, it is likely that 
participants would have developed a level of acclimation to these conditions. 
Consequently, resting eHsp72 concentration prior to the commencement of the final 
MDS stage would likely have been greater than recorded pre-race values (McClung 
et al., 2008). This speculation could aid understanding regarding the less substantial 
increase in eHsp72 post-exercise in comparison to previous ultramarathon research 
(Gomez-Merino et al., 2006; Suzuki et al., 2006). Boshoff et al. (2000), Gjøvaag and 
Dahl (2006), and Sandström et al. (2008) have shown that participants with high pre-
exercise Hsp70 concentration displayed smaller increases in post-exercise values in 
vivo. Sandström et al. (2008) also demonstrated an increase in basal Hsp70 over a 
15-day acclimation period, which indicates the possibility of elevated resting eHsp72 
Present study 
data collection 
time point  
  56
prior to commencement of the final stage in the present study. Although evidently 
not directly quantifiable in this study, it can be speculated that prior to 
commencement of the final race stage, resting eHsp72 would have been greater than 
the recorded pre-race values, and thus post-race eHsp72 may have displayed a less 
substantial increase than those seen in previous studies (Gomez-Merino et al., 2006; 
Suzuki et al., 2006) due to the potential role of heat acclimation (Sandström et al., 
2008). Evidently, the inclusion of daily data collection upon stage completion would 
provide the data required to quantify this speculation, which should be considered 
for future studies investigating multi-day ultra-endurance events. 
 
To summarise PRO and PGLn supplementation regimes were ineffective to i) 
increase basal eHsp72 values pre-race and ii) ameliorate the eHsp72 response seen in 
all groups post-race. 
 
3.4.3 LPS Response  
 
No significant change (p > 0.05) in circulatory LPS concentration from baseline to 
post-race was observed within the present study. This is in contrast to hypothesis 
four and opposes the findings from a number of previous studies in which endurance 
(Ng et al., 2008) and ultra-endurance (Costa et al., 2014; Jeukendrup et al., 2000) 
exercise have initiated a significant increase in circulatory LPS concentration. 
Jeukendrup et al. (2000) demonstrated a significant rise in LPS concentration and 
mild endotoxemia in 68% of athletes following an ironman distance triathlon. 
However, whilst Jeukendrup et al. (2000) demonstrated that endotoxemia was 
present in 68% of athletes 1 h post-race, this reduced to just 19% 2 h post-race, 
before increasing further to 79% 16 h post race. Figure 3.9, adapted from Jeukendrup 
et al. (2000), demonstrates changes in post-race LPS concentration, and indicates the 
time-point at which data was collected in the present study. As shown, LPS 
concentration at this time-point was clearly lower than the LPS concentration 
observed at 1h post-race. This suggests that samples collected between 6 – 8 h post-
race in the present study may have occurred during the trough phase, and thus data 
collection immediately/ within 1 h post-race could have demonstrated higher LPS 
values with the present study. However, Jeukendrup et al. (2000) did not collect 
hourly samples, and to the author’s knowledge no study has been conducted to 
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validate the time-course of LPS translocation following exercise, and thus this theory 
is only speculative. Future research exploring the time-course of post-exercise LPS 
translocation should utilise the standardised and pharmacologically optimised PRO 
supplement proposed earlier within this section. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. LPS concentration before, and at several time points following, an 
ironman triathlon, demonstrating the potential LPS response at the time of data 
collection in the present study; adapted from Jeukendrup et al. (2000). 
 
In addition to this, it may be postulated that the beneficial effects of the 
supplementation regimes were beginning to reduce towards the end of the race. 
Previous studies have established that the typical time-course for passage of 
probiotic bacteria through the GI tract is 3-8 days (Klijn et al., 1995), and it is still 
unclear as to whether these remain metabolically active in the GI tract, making it 
difficult to conclude whether the effects of the supplementation were present during 
the MDS. It is possible that the effect was still present, previous research 
investigating the effects of probiotic supplementation utilising repeated measures 
designs have commonly implemented washout periods of between 3 (Shing et al., 
2014) and 6 (Rosenfeldt et al., 2004) weeks, which may suggest that the effects 
remain for more than 7d following the termination of supplementation. However, to 
Present study data 
collection time 
point  
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the author’s knowledge, there is a lack of evidence to demonstrate the duration that 
the effect persists, thus this is purely speculation, and further research is required to 
obtain a greater understanding.  
 
Furthermore, although endotoxemia is reportedly common amongst endurance and 
ultra-endurance athletes (Ter Steege et al., 2008), it has been shown that “training” 
the gut is a potential method by which levels of GI discomfort and LPS 
translocation/endotoxemia can be significantly reduced and/or avoided during these 
events (Carrio et al., 1989; Selkirk et al., 2008). Murray (2006) stated that proper 
training and nutrition reduces the risk of GI discomfort during exercise by 
maintaining adequate perfusion of the splanchnic vasculature – a key contributor to 
intestinal wall damage and subsequent LPS translocation [section 2.3.2; Moses 
(2005)]. Carrio et al. (1989) reported enhanced gastric emptying rates in endurance 
athletes, with support from Gisolfi (2000), stating that splanchnic blood flow is 
greater in trained athletes at any given workload, and thus improved gut barrier 
function commonly occurs with training as a result of enhanced blood flow. Selkirk 
et al. (2008) also demonstrated significantly lower levels of plasma LPS in trained 
individuals compared to untrained at a given absolute Tcore during exercise in the 
heat. This training effect may be further enhanced in events, such as the MDS, where 
exercise is performed on consecutive days, again highlighting the possibility of the 
aforementioned habituation effect, and the requirement of daily sample collection in 
future research studies to quantify this postulation. These studies suggest that trained 
individuals are less likely to suffer from endotoxemia during exercise heat-stress.  
 
The participants in this study were well trained (overall average pre-race V O 
57.55 ± 2.09 ml.kg.min-1), and thus it could be suggested that the lack of increase in 
post-race circulatory LPS concentration may be attributed to a sufficient level of 
splanchnic blood flow during exercise, as a result of enhanced training status, which 
may subsequently reduce the severity of GI damage. A significant increase (p < 
0.05) in V O was displayed from baseline to pre-race in all groups, indicating a 
significant training effect over time. Additionally, as no difference in GI discomfort 
between groups was demonstrated throughout the MDS, it is likely that the training 
status of the individuals was a more potent contributor to the GI response, as no 
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effect of group (p > 0.05) was observed for overall fitness based upon average 
V O. It is important to note that gut blood flow was not measured in this study 
and therefore further research into this theory should be conducted, potentially 
utilising measures of splanchnic blood flow, in addition to daily sample collection, to 
demonstrate the effect of ultra-endurance exercise on the trained athlete’s gut. 
 
As no significant increase in LPS concentration (p > 0.05) occurred in the present 
study, and no significant correlation (r2 = -.122, p > 0.05) was found between 
eHsp72 and LPS concentration following exercise, it is difficult to draw conclusions 
regarding the relationship between the two variables. These findings suggest no 
significant interaction was present between LPS and eHsp72 concentration. Previous 
research has highlighted the role of eHsp72 on LPS tolerance [section 2.3.3 (Aneja et 
al., 2006)], higher concentrations of eHsp72 have been associated with increased 
LPS tolerance through reduced pro-inflammatory cytokine release in response to 
LPS (Ferat-Osorio et al., 2014). Thus, it can be speculated that the elevated eHsp72 
concentration observed post-race may have contributed to an elevated LPS tolerance. 
This cannot be quantified in the present study due to the absence of pro-
inflammatory cytokine analysis (i.e. TNF-α, IL-6), and thus this postulation also 
requires further investigation. 
 
In addition, despite no significant correlation between eHsp72 (r = - 0.008, p = 
0.962) or LPS (r = 0.128, p = 0.470) concentration and MDS finishing time, a 
significant effect of group on finishing time was displayed, whereby the PRO group 
completed the race significantly faster than CON. As stated, two participants were 
disqualified from the race due to the failure to complete a stage within the required 
time, however, when analysed both including and excluding these participants, the 
CON group remained significantly slower on average in comparison to the PRO 
group, suggesting that the disqualified participants’ time did not alter the results of 
the analysis. These findings are difficult to explain, as there was no effect of group 
on post-race eHsp72 or LPS concentration and thus these variables cannot be 
confirmed as the cause of the observed difference in finishing times. Furthermore, no 
significant difference in fitness levels was demonstrated between groups, which 
therefore suggests that a confounding variable, potentially related to the ingredients 
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of the PRO supplementation (as postulated in section 3.4.2), was responsible for this 
outcome. Due to the prolonged duration of the intervention, participants were not 
blinded to condition, which may have caused a demotivational response, and 
potentially led to impaired performance in the CON group through a reverse placebo, 
also known as nocebo, effect (Carlino et al., 2014). However, it is difficult to reach a 
clear conclusion regarding the role of supplementation upon performance, as this 
was not a main outcome variable of the present study, additional research is 
therefore required to further investigate the effect of this supplementation upon 
ultramarathon performance, in order to demonstrate whether supplementation for GI 
distress can have a significant impact upon overall performance. 
 
In addition to this, the baseline LPS concentrations (Table 3.2) were higher than 
expected in all groups. As endotoxemia is defined as an LPS concentration > 
5pg/ml, the results of the present study indicate that all participants were in a state of 
endotoxemia at baseline. This result was unexpected and may indicate the possibility 
of LPS sample contamination in this instance. However, all procedures during 
testing followed the correct guidelines, in an attempt to ensure that all samples were 
protected against contamination, and as a result, it was deemed appropriate to 
include these results as baseline levels in the present study, as contamination is only 
one possible explanation as to the cause of these unexpected results. Although it is 
recognised that these results are seemingly high in comparison to previous research, 
the author deemed it appropriate to report the data, and display results as a 
percentage change from these baseline values, as all procedures and protocols 
throughout the study were followed correctly. Additionally, whilst the majority of 
previous literature would suggest that these results are high, this is not the first study 
to display above average baseline values. Lim et al. (2009) displayed pre-exercise 
values >10pg.ml-1, which supports the data in the present study. Future research 
should aim to investigate a clear explanation as to why baseline LPS values may be 
high in certain individuals. Future research should also focus upon minimising the 
risk of contamination, by ensuring that endotoxin-free tubes are used and are kept in 
a sterile environment, gloves are worn at all times when handling samples, and the 
appropriate pipette tips are used during analysis.  
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3.4.4 Synthesis of findings 
 
The findings observed in the present study primarily demonstrate the key role of 
ultra-endurance exercise on the eHsp72 response, and suggest that PRO and PGLn 
supplementation may be ineffective nutritional interventions to induce an increase in 
basal eHsp72 concentration in humans. Additionally, previous research is largely in 
agreement that participation in ultra-endurance events stimulates a substantial 
increase in circulatory LPS concentration in single day events (Brock-Utne et al., 
1988; Jeukendrup et al., 2000). The severe level of stress imposed upon the gut 
during such exercise leads to intestinal epithelial cell and tight junction damage (Van 
Wijck et al., 2011), causing a subsequent increase in GI mucosal membrane 
permeability, and thus an undesirable increase in LPS translocation (Berkes et al., 
2003). However, the multi-day ultra-endurance exercise undertaken in the present 
study did not lead to a significant increase in LPS concentration across all groups, 
which was an unexpected outcome. This may be attributable to a habituation and 
acclimation effect across the duration of the event, which should be measured in 
future studies via daily sample collection. The following sections will explain the 
practical applications (section 3.4.5) of the present study, and will subsequently 
discuss the experimental limitations (section 3.4.6) and highlight recommendations 
for future research (section 3.4.6) based upon these findings. The novel data 
collected in the present study should be utilised to enhance future research design 
and develop the currently limited knowledge surrounding this field of research, with 
a particular focus on ultra-endurance exercise. 
 
3.4.5 Application of findings 
 
This study aimed to investigate the effects of chronic probiotic supplementation on 
LPS translocation and the eHsp72 response following an ultra-endurance event in 
extreme environmental conditions. As stated in section 2.2.1, ultra-endurance events 
are becoming increasingly popular (Knechtle et al., 2011), and, as a result, 
investigations into methods that could attenuate detrimental side effects and 
ultimately optimise performance are highly desired. The findings from the present 
study are in contrast to previous research, which has inferred a significant beneficial 
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role of probiotic supplementation upon GI permeability and athletic performance 
(Kekkonen et al., 2007; Lamprecht et al., 2012; Shing et al., 2014). The present 
study indicates that chronic PRO and PGLn supplementation interventions are 
ineffective in relation to the LPS and eHsp72 response to multi-day ultra-endurance 
events. It is suggested that an adequate level of training (likely heat acclimation) 
prior to the event could be sufficient to blunt the detrimental LPS response 
commonly associated with ultra-endurance events, and subsequently prevent the 
previously established GI-related decrement in performance (Riddoch and Trinick, 
1988). 
 
3.4.6 Experimental limitations and future research 
 
Limitations have been highlighted in relation to the experimental procedures of the 
present study, which should be considered when interpreting results and undertaking 
future research. Due to the collection of novel data with extremely high external 
validity in a field-based research design, control of certain aspects of the study were 
undesirably compromised in places. The principal limitations of the present study 
were the time period elapsed between race completion and venous blood sample 
collection, and the frequency of sample acquisition within race. Ideally, daily venous 
blood sample collection would have occurred immediately prior to and post stage 
completion (or within ~30 min) in accordance with previous research (Gomez-
Merino et al., 2006; Suzuki et al., 2006) to reduce the influence of confounding 
factors (as discussed in sections 3.4.2 and 3.4.3) on plasma samples and to increase 
understanding regarding the changes in eHsp72 and LPS concentration throughout 
the duration of the event. However, the logistical issues associated with field-based 
research heavily influenced post-race blood sample collection in the present study. 
As a result, post-race blood samples, originally scheduled for ~ 1-2 h post-exercise, 
were delayed to a range of 6 – 8 h post-exercise, which may have resulted in 
alterations in the observed LPS and eHsp72 concentration. Future research should 
aim to eliminate this confounding factor, by collecting post-race samples as close to 
race completion as possible (preferably within 1 h post exercise). This will give a 
truer representation of the eHsp72 and LPS response to the exercise undertaken. This 
limitation highlights a major confounding factor in the present study and provides a 
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potential explanation for the observed, seemingly low, post-race LPS concentration 
in all groups.  
 
Furthermore, the analysis of variables at additional time points could contribute to 
obtaining more detailed, reliable results regarding the response to multi-day 
ultramarathon performance. Future research should investigate the eHsp72 and LPS 
response to each individual stage, as well as to the overall race, by collecting daily 
samples upon stage completion. This would provide further novel data, 
demonstrating the impact of consecutive bouts of prolonged endurance running in 
extreme environmental conditions on GI permeability, and the eHsp72 response. 
Due to the logistical restraints of the MDS (taking place in the Sahara Desert - a 
restrictive environment for data collection), collection of daily samples and 
immediate post-race samples was unfortunately not possible. Future studies 
investigating multi-day ultra-endurance events in more accessible environments 
should consider this recommendation, in order to obtain more robust, detailed 
information regarding these specific cellular responses. In addition to this, it may 
also be suggested that future research should consider implementing sample 
collection through alternative methods, such as urine or saliva samples. However, 
whilst it is possible that these samples could be collected without experimenter 
supervision, it is likely that accuracy of samples would be affected by lack of control 
and the impact of sterility upon samples. Future research should investigate a method 
by which within-race samples can be collected, whilst reducing the risk of impaired 
data output. Additional markers, such as iHsp72 and pro-inflammatory cytokine 
analysis, could also be included in future studies; these markers could provide 
further understanding regarding the immunological and protective role of the heat 
shock response following such exercise, with greater focus upon the link between 
eHsp72 and innate immunity (Asea, 2003).  
  
The PRO and PGLn supplements and dosage implemented in the present study may 
have also strongly influenced the outcome. As stated, it is possible that these 
commercially available products contained additional ingredients that may have 
acted as confounding factors (Maughan, 2005), and subsequently influenced the 
observed eHsp72 and LPS response. This limitation should be addressed in future 
research, whereby the development of a standardised and pharmacologically 
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optimised PRO supplement strain is essential in order to improve reliability and 
generalisability. This could subsequently improve the quality control of PRO 
supplementation, an issue previously highlighted by Tuomola et al. (2001), and 
could therefore reduce the impact of confounding variables upon results. 
 
Moreover, the implemented PRO and PGLn dosage may have been insufficient to 
induce the hypothesised eHsp72 and LPS response. The use of a standardised dose 
for all participants in the present study may have caused varying responses between 
individuals, whereas previous in vivo research has commonly implemented a dose 
relative to participants’ body mass (Zuhl et al., 2014; 2015) which may have led to a 
more specific and generalisable response between participants. Future research 
should consider investigating the optimal dose required to initiate the proposed 
eHsp72 response, which could consequently be implemented in future research 
designs, in order to enhance generalisability across the field. 
 
It is also possible that as participants were not blinded to group assignment, a nocebo 
effect (Carlino et al., 2014) may have taken place in the CON group, and may have 
influenced overall race performance, however, this is purely speculation. Future 
research should consider the effect of blinded groups upon findings, in combination 
with the implementation of a placebo supplement in the CON group, in order to 
reduce the risk of a nocebo effect taking place. 
 
As aforementioned (section 2.3.3), research has demonstrated a key role of eHsp72 
on LPS tolerance (Aneja et al., 2006). A greater insight into the in vivo relationship 
between eHsp72 and LPS could be elucidated via the inclusion of pro-inflammatory 
cytokine analysis (i.e. TNF-α, IL-6), to infer a greater understanding regarding the 
role of eHsp72 upon LPS tolerance in humans. Participation in a highly stressful, 
multi-day event, such as the MDS, may induce LPS tolerance in humans; however, 
this cannot be quantified in the present study, due to the absence of pro-
inflammatory cytokine analysis. This highlights the need for future research to build 
upon the present study, and to enhance the findings to broaden understanding 
regarding the relationship between the eHsp72 and LPS response to ultra-endurance 
exercise. 
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In addition, Lee et al. (2015) recently suggested that the commercially available 
eHsp72 ELISA kit (HSP70 high sensitivity ELISA kit, Enzo Life Sciences, Exeter, 
UK) utilised in the present study offers less precise results in comparison to a newly 
available alternative ELISA kit (ENZ-KIT-101-001 HSP70 Amp'd® ELISA). Lee et 
al. (2015) subsequently recommended that utilizing the new ENZ-KIT-101-001 
HSP70 Amp'd® ELISA kit will provide a more accurate measure of resting eHsp70 
quantification, due to the increased sensitivity of this assay. Thus, it is suggested that 
in line with these recommendations, future research should utilize this newly 
developed ELISA kit. Use of this kit could offer more accurate quantification of 
eHsp72 concentration, which, in the present study, could have provided a clearer 
insight regarding the effect of PRO and PGLn supplementation on the eHsp72 
response pre-race. 
 
Finally, greater control over the training and nutritional programmes undertaken by 
participants over the 12 wk intervention period would have allowed for enhanced 
control and reliability regarding the source of specific conclusions of the 
investigation. Future studies should consider implementing a standardised training 
and nutrition programme for all experimental groups, in order to reduce the impact 
of confounding variables. In addition, the inclusion of these programmes would 
elucidate a clearer understanding regarding the role of nutrition and training upon 
LPS translocation and the subsequent eHsp72 response to ultra-endurance exercise. 
 
3.5 Conclusion 
 
In conclusion, the present study has demonstrated that nutritional interventions of 
chronic PRO and PGLn supplementation are not required in order to reduce LPS 
translocation and GI discomfort during ultra-endurance performance in extreme heat. 
A high level of fitness may induce physiological adaptations that could improve 
overall gut health, and the increased eHsp72 concentration in response to exercise 
may offer cytoprotection and aid the reduction of GI discomfort during performance. 
Future investigations should aim to build upon this field-based research, but should 
include additional markers of GI damage, and pro-inflammatory cytokine analysis 
(i.e. TNF-α, IL-6), to offer a greater level of understanding regarding the relationship 
between eHsp72 and LPS concentration. Future research should also aim to collect 
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samples immediately/ within 1 h of race completion in order to obtain a more 
accurate representation of the physiological and biological responses to ultra-
endurance exercise in extreme environments.  
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CHAPTER 5: Appendices  
 
Appendix A  
 
Participant Information Sheet  
Section A: The Research Project 
 
Title of project: Chronic Probiotic Supplementation and its Effects on eHsp72 and 
LPS concentration following a Desert-based Ultramarathon 
 
1. Purpose and value of study: The purpose of the study is to investigate the 
impact of nutritional intake prior to a multi-day ultra-endurance event. With 
the ever-increasing numbers of athletes of all levels competing in ultra-
endurance events a greater understanding of the demands placed on the body 
by these events is required.  
 
2. Invitation to participate: You are being invited to take part in a research 
study. Before you decide whether to do so, it is important that you 
understand the research that is being done and what your involvement will 
include. Please take the time to read the following information carefully and 
discuss it with others if you wish. Do not hesitate to ask us anything that is 
not clear or for any further information you would like to help you would 
like to help make your decision. Please do take your time to decide whether 
or not you wish to take part. Thank you for reading this.  
 
3. Who is organising the research: The research is being organised by Craig 
Suckling under the supervision of Dr Justin Roberts and Dr Dan Gordon 
from Anglia Ruskin University in collaboration with Hannah Marshall and 
Dr Lee Taylor from the University of Bedfordshire. 
 
4. What will happen to the results of the study: If you agree to take part, 
your results will be stored on a password protected computer and portable 
disk drive, with your name and other details removed. Blood samples will be 
collected, stored securely and disposed of under Human Tissue Authority 
regulations. The samples will be analysed for endotoxin units and heat shock 
proteins only. The research team at Anglia Ruskin University will keep all 
paper data securely. We expect the data will be published in a scientific 
journal and presented at a scientific conference. On publication of the results 
it will not be possible to identify individual participants. 
 
5. Source of funding for the research: The research is funded by the lead researcher. 
 
6. Contact for further information: craig.suckling@student.anglia.ac.uk or 
Hannah.marshall1@study.beds.ac.uk  
 
Section B: Your Participation in the Research Project 
 
1. Why you have been invited to take part: You have been invited to 
participate in the research because you have entered the 2015 Marathon des 
Sables and expressed an interest in taking part in the research project. 
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2. Whether you can refuse to take part: You are under no obligation to participate in 
the study. 
 
3. Whether you can withdraw at any time, and how: You are free to 
withdraw without reason and without penalty from the study at any time. If 
you wish to withdraw from the study please complete the withdrawal form 
on the bottom of the consent form and return it to the research organiser. 
 
4. What will happen if you agree to take part (brief description of 
procedures/tests): 
 
 The study will take place in 3 phases: 
 
PRE event testing will take place at Anglia Ruskin University (January 8th-
13th and March 26th-31st) Testing slots can be booked on a first come first 
served basis through the lead researcher.  
 
EVENT testing will take place during the 2015 Marathon Des Sables (3rd -
13th April) at Berbere Hotel, Ouarzarate. As you return upon completion of 
the race.  
 
POST event testing will take place at Middlesex University (16th – 20th 
April). Testing slots can be booked on a first come first served basis through 
the lead researcher.  
  
If you decide to take part in the study you will be required to attend all 3 
phases; details of the procedures you will undergo are detailed below.  
 
Body composition assessment (All phases) during which your height (m), 
Body mass (kg) will be measured. You will also undergo body fat 
estimation using skinfold and segmental measures. Please note that you will 
be required to wear loose fitting sports kit (female participants a sports bra is 
required); the procedure can be performed by a gender-matched researcher if 
requested. (Approximate time commitment 20-40 mins) 
 
Resting blood sample (All phases) a single blood sample (3x4ml samples) 
will be collected from your arm. The procedure will be carried out by a 
trained phlebotomist. You will be required to refrain from food/drink 
(except water) for 6 hours prior to the test. (Approximate time commitment 
10 mins) 
 
Maximal oxygen uptake test (VO2MAX) (Pre phase only) a short duration 
incremental exercise treadmill test for the determination of the highest 
absolute oxygen uptake value. You will run on a treadmill in 2 minute stages 
of progressive intensity, while oxygen uptake is measured. (Approximate 
time commitment 20-40 mins)  
 
Nutritional Intervention you will be randomly assigned to 1 of 3 
experimental groups for the duration of the study. Depending on the group 
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you are assigned to you may be required to take a supplement or maintain 
habitual diet. Each group will be briefed individually as to the exact 
requirements (approximate time commitment none) 
 
5. Whether there are any risks involved (e.g. side effects from taking part) 
and if so what will be done to ensure your wellbeing/safety: Research of 
this nature has a number of potential risks, however every effort has been 
made to minimise the nature of these risks and ensure your wellbeing. 
Body composition - possible but highly unlikely risks include: discomfort or 
skin irritation from skinfold/ segmental location and assessment. All 
research testers are experienced in skinfold and anthropometrical 
assessment.  
 
Resting blood collection – possible risks include: dizziness/fainting/ nausea 
from blood collection procedure; localised bruising. All venepuncture 
procedures will be undertaken by qualified phlebotomists only. 
 
Maximal exercise testing – potential risks may include: fatigue/ tiredness 
and localised muscle soreness following exercise exertion. Participants will 
complete appropriate warm up and cool down, two testers who are first aid 
trained will be conducting the test.  
 
Nutritional supplementation (12 weeks) – possible acute side effects 
(nausea, dizziness, bloating, gastrointestinal distress from consumption). All 
nutritional products will be supplied by a highly reputable clinical nutrition 
company: Biocare Nutrition Ltd., and are commercially available to the UK 
general public. 
 
Risk assessments have been carried out and reviewed at each testing location. 
Throughout the testing procedures standard operating procedures for each 
location will be followed by the research team.  
 
6. Agreement to participate in this research should not compromise your 
legal rights should something go wrong: Participation does not 
compromise your legal rights should anything go wrong. Suitability of the 
entrants to participate in the event and full liability falls under the race 
organiser’s regulations and is not part of the study. 
 
7. Whether there are any special precautions you must take before, during 
or after taking part in the study: All participants are recommended to 
avoid strenuous exercise 48 hours prior to PRE event testing session. Avoid 
food and drink (except water) for 6 hours prior to PRE and POST event 
resting blood samples and for 2 hours prior to EVENT resting blood sample. 
No use of nutritional supplements that promote/improve gut health directly 
or indirectly for the duration of the study, the lead researcher will provide 
details of supplements that cannot be used. 
 
8. What will happen to any information/data/samples that are collected 
from you: Any information/data/samples collected form you as part of the 
study will be stored anonymously in accordance with current legislation and 
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Anglia Ruskin University policy. The blood samples will be analysed to 
assess the levels of endotoxin units and heat shock proteins present. The 
study will be written up using the information and data collected as part of a 
PhD/Masters thesis and for publication in a scientific journal. It will not be 
possible to identify individual participants from the published work. 
 
9. Whether there are any benefits from taking part: By taking part in the 
study you will receive the following benefits: 
 
High quality fitness assessment including maximal oxygen uptake (VO2MAX) 
Generic dietary advice.   
Free accurate assessment of your body composition. 
Access to two Marathon Des Sables finishers  
 
10. How your participation in the project will be kept confidential: All 
subjects will be randomly assigned a numeric code; all data will be collected 
and stored under this code. Collected data will be stored in a secure manner 
to maintain confidentiality and anonymity.  
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Appendix B  
 
Consent Form  
 
NAME OF PARTICIPANT: 
 
Title of the project: Chronic Probiotic Supplementation and its Effects on eHsp72 
and LPS concentration following a Desert-based Ultramarathon 
 
Main investigator and contact details: Craig Suckling Craig.suckling@student.anglia.ac.uk , 
Hannah Marshall: Hannah.marshall1@study.beds.ac.uk  
 
Members of the research team: Dr Justin Roberts, Dr Dan Gordon, Dr Mike Roberts, Dr Lee 
Taylor. 
 
1. I agree to take part in the above research. I have read the Participant 
Information Sheet for the study. I understand what my role will be in this 
research, and all my questions have been answered to my satisfaction. 
 
2. I understand that I am free to withdraw from the research at any time, for any 
reason and without prejudice. 
 
3. I have been informed that the confidentiality of the information I provide will be 
safeguarded. 
 
4. I am free to ask any questions at any time before and during the study. 
 
5. I have been provided with a copy of this form and the Participant Information Sheet. 
 
Data Protection: I agree to the University processing personal data which I have 
supplied. I agree to the processing of such data for any purposes connected with the 
Research Project as outlined to me* 
Name of participant (print)………………………………………………………………… 
Signed………………..……………………………………………………………………… 
Date 
 
If you wish to withdraw from the research, please complete the form below and 
return to the main investigator named above. 
 
 
I WISH TO WITHDRAW FROM THIS STUDY: Signed: 
__________________________________        Date: _____________________ 
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Appendix C 
 
Participant Health Screen Questionnaire  
 
 
PRE-PARTICIPATION HEALTH SCREEN QUESTIONNAIRE 
 
 
Name of participant: 
     
It is important when having volunteered as a participant for this study, and having 
read the briefing sheet for all participants that you answer the following questions. 
Please do not answer any questions if you consider them intrusive, instead speak to 
Dr J Roberts. 
 
 
 
1) Are you currently aged between 18-60 years, and consider yourself 
recreationally active?  
Yes No 
 
 
2) Are you pregnant? 
 
 
 
 
3) Do you suffer from diabetes or low blood sugar (hypoglycaemia)? 
 
Yes No 
 
 
4) Is there any history of diabetes or low blood sugar in your immediate family? 
Yes No 
 
 
5) Do you suffer from high blood pressure, or any heart problems? 
 
Yes No 
 
 
6) Do you often get dizzy, or do you know that you have low blood pressure? 
 
Yes No 
 
Yes No 
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7) Is there any history of heart disorders or heart disease in your immediate 
family? 
Yes No 
 
8) Do you, or have you suffered from any blood related disorders, or have you 
any issues related to blood taking?      
Yes No 
9) Have you suffered from any recent viral infections? 
 
Yes No 
 
10) Are you suffering from any musculo-skeletal injury? 
 
Yes No 
 
11) Are you currently taking any medication (over the counter, or prescription)? 
 
Yes No 
 
(You do not need to answer “Yes” if you are an asthmatic with an inhaler 
available; or if taking a contraceptive pill) 
 
 
12) Have you ever been told that you should not exercise? 
 
Yes No 
 
13) Do you feel fully fit, and eager to act as study participant? 
 
Yes No 
14) Are you under the influence of alcohol or any other psycho-active substance? 
  
Yes No 
 
Is there any reason, not stated above, why you cannot take part as a participant in 
this project? 
 
Yes No 
 
Signature…………………………………………………..   Date: 
 
 
Checked by (Name):       Date: 
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                                            COMMERCIALLY SENSITIVE INFORMATION STRICTLY FOR INTERNAL USE ONLY 
 
Confidential Page 1 08/10/2014 
PRODUCT MASTER FILE 
 
FULL PRODUCT SPECIFICATION 
 
PRODUCT 
NAME 
 Bio-Acidophilus Forte 
PRODUCT TYPE Vegetable Capsules 
CATEGORY Probiotics 
ONLINE/    
PRICE LIST 
DESCRIPTOR 
BioAcidophilus Forte (Probiotic) 30 Caps 
BioAcidophilus Forte (Probiotic) 60 Caps 
 
 
PRODUCT DESCRIPTOR (on label under the product name) 
 
Professional Potency Friendly Bacteria 
 
 
PRODUCT INFORMATION PER DAILY INTAKE (1Capsule)  
 
Ingredient Amount  
 
Lactobacillus acidophilus  100mg 
(CUL-60 & CUL-21) 
Fructooligosaccharides (F.O.S.)  60mg 
Bifidobacterium bifidum (CUL-20)  22.2mg 
& Bifidobacterium lactis (CUL-34) 
Providing a total of 30 billion viable proprietary organisms 
 
 
INGREDIENTS 
Lactobacillus acidophilus, Bulking Agent (Cellulose), Capsule Shell (Hydroxypropyl Methylcellulose), 
Fructooligosaccharides, Bifidobacterium bifidum & Bifidobacterium lactis, Anti-Caking Agents (Silicon Dioxide 
and Magnesium Stearate). 
 
 
FULL ALLERGEN DETAIL: 
 
Added Yeast no GM Free yes Dairy Free yes Low Salt - 
Wheat Free yes 
With Added 
Sugar 
yes 
With Added 
Salt 
no No Salt - 
Gluten Free yes 
No Added 
Sugar 
- Kosher no Halal no 
 
 
SUITABILITY:   
 
Vegetarian yes Vegan yes Organic - Can Open capsule yes 
Pregnancy yes Breastfeeding yes Children -   
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                                            COMMERCIALLY SENSITIVE INFORMATION STRICTLY FOR INTERNAL USE ONLY 
 
Confidential Page 2 08/10/2014 
LABEL CAUTIONS/ADVISORY STATEMENTS: 
 
 
If you are under medical supervision, please consult a doctor before use 
 
This product should not be used as a substitute for a varied and balanced diet and healthy lifestyle. 
 
Do not exceed the stated recommended daily intake. 
 
Do not purchase if the seal is broken. 
 
Keep out of reach of children. 
 
Refrigerate below 4oC and avoid direct sunlight and heat. 
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                                            COMMERCIALLY SENSITIVE INFORMATION STRICTLY FOR INTERNAL USE ONLY 
 
Confidential Page 1 08/10/2014 
PRODUCT MASTER FILE 
 
FULL PRODUCT SPECIFICATION 
 
PRODUCT 
NAME 
 GI Complex 
PRODUCT TYPE Powder 
CATEGORY Gastrointestinal 
ONLINE/    
PRICE LIST 
DESCRIPTOR 
GI Complex 165g 
 
PRODUCT DESCRIPTOR (on label under the product name) 
 
L-Glutamine, N.A.G and Probiotic Complex 
 
 
PRODUCT INFORMATION PER DAILY INTAKE per 5g dose (2 teaspoons) 
 
Ingredient Amount % EC RDA* 
Vitamin A 5000iu 1500μg  RE
†
 188 
Vitamin E 45iu 30mg α-TE
††
 250 
Vitamin C 180mg 225 
Magnesium 12.3mg 3.3 
Zinc 20mg 200 
Whey Protein 1800mg -  
L-Glutamine 900mg - 
Fructooligosaccharides (FOS) 500mg -  
N-Acetyl Glucosamine 435mg -  
Ginger Powder 300mg - 
Evening Primrose Oil 33mg -  
(Providing 3.3mg Gamma Linolenic Acid) 
Lactobacillus acidophilus (CUL-60 40.5mg - 
CUL-60 & CUL 21)  
Lactobacillus salivarius (CUL-61)  25mg - 
Bifidobacterium bifidum  3.5mg - 
(CUL-20) Bifidobacterium lactis (CUL-34)  - 
(providing a total of 10 billion viable organisms)  
 
RE
† = 
Retinol
 
Equivalent 
α-TE
†† = 
Alpha Tocopherol Equivalent 
RDA = Recommended Daily Allowance 
INGREDIENTS 
 
Whey Protein Concentrate
1
, L-Glutamine, Fructooligosaccharides (FOS),  N-Acetyl Glucosamine
2
, Ginger 
Powder (Zingiber Officinalis root), Vitamin C (as Magnesium Ascorbate), Zinc Citrate, Vanilla Flavour, 
Lactobacillus acidophilus, Silicon Dioxide, Evening Primrose Oil, Modified Tapioca Starch, Potato Maltodextrin, 
Vitamin E (as D-Alpha Tocopheryl Acetate), Lactobacillus salivarius, Acacia Gum  Sucrose, Corn Starch, 
Bifidobacterium bifidum, Bifidobacterium lactis, Vitamin A (as Retinyl Acetate) Antioxidants (Ascorbic Acid, 
Ascorbyl Palmitate & Natural Mixed Tocopherols), Corn Oil, Sunflower Oil  DL-Alpha Tocopherol. 
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                                            COMMERCIALLY SENSITIVE INFORMATION STRICTLY FOR INTERNAL USE ONLY 
 
Confidential Page 2 08/10/2014 
FULL ALLERGEN DETAIL: 
 
Added Yeast No  GM Free Yes  Dairy Free No  Low Salt - 
Wheat Free Yes  
With Added 
Sugar 
Yes  
With Added 
Salt 
No  No Salt -- 
Gluten Free Yes  
No Added 
Sugar 
- Kosher - Halal - 
 
 
SUITABILITY:   
 
Vegetarian x Vegan x Organic x Can Open capsule x 
Pregnancy x Breastfeeding x Children x   
 
 
 
RECOMMENDED INTAKE: 
 
Two teaspoons (approx. 5g) mixed well in water and taken daily with food or as professionally directed. 
 
 
 
 
 
LABEL CAUTIONS/ADVISORY STATEMENTS: 
 
 
If you are under medical supervision, please consult a doctor before use 
This product contains vitamin A. Do not take if you are pregnant or if you are likely to become pregnant 
except on the advice of a doctor or ante-natal clinic 
This product should not be used as a substitute for a varied and balanced diet and healthy lifestyle. 
Do not exceed the stated recommended daily intake. 
Do not purchase if the seal is broken. 
Keep out of reach of children. 
Refrigerate below 4oC and avoid direct sunlight and heat. 
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Appendix F  
 
 
Marathon Des Sables Research Study 
 
RACE GASTROINTESTINAL SYMPTOM QUESTIONNAIRE 
 
 
Q: Did you stick to your pre-race nutritional strategy? If not, please describe what 
you changed. 
 
 
 
Q: Please grade the quality of your sleep before each stage (0=no sleep; 3= low 
quality; 5 = medium quality (broken sleep); 7 = good quality/ unbroken; 10 = high 
quality/unbroken) 
 
0 1 2 3 4 5 6 7 8 9 10 
 
 
          
 
 
DURING EACH STAGE  
Please indicate whether the following apply to you  
(0=never or rarely; 1 = low severity; 2 = moderate severity; 3 = high severity) 
 
Time taken = 0 1 2 3 
Symptom      
1-General urge to urinate     
2-General urge to defecate     
3-Bloating severity     
4-Belching severity     
5-Flatulence severity     
6-Nausea     
7-Stomach/intestinal pain or discomfort     
8-Stomach/ intestinal cramping     
9-Headaches     
10-Dizziness     
 Roberts, J.D. & Roberts, M.G. (2013) 
 
 
Q: Did you think you suffered from any symptoms of endotoxemia? If yes, please 
grade the severity below (0=no evidence; 1= very mild; 3 = mild; 5 = moderate 
symptoms/ only part of either day; 7 = severe/ over full day 1 or 2; 10= very severe/ 
ill): 
0 1 2 3 4 5 6 7 8 9 10 
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Appendix G  
 
Baseline eHsp72 ELISA plate layout  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Std 3 Std 7 SM10 SM52 SM48 SM08 SM15 SM11 SM44 SM53 SF03 
B Blank Std 3 Std 7 SM51 SM05 SM31 SM19 SF01 SF05 SM15 SM26 SM55 
C S0 Std 4 SM42 SM55 SM39 SM25 SF10 SM04 SM38 SM40 SM05 SM48 
D S0 Std 4 SM06 SF06 SM26 SM47 SF07 SM35 SM20 SM19 SM49 SM31 
E Std 1 Std 5 SM02 SM13 SF04 SM53 SM40 SM27 SM54 SM24 SF02 SM03 
F Std 1 Std 5 SM43 SF02 SM32 SM24 SM45 SM44 SM17 SM32 SF06 SM33 
G Std 2 Std 6 SM30 SM29 SM18 SM50 SM07 SM36 SM28 SM03 SM06 SF10 
H Std 2 Std 6 SF03 SM49 SM03 SM33 SF09 SF11 SM20 SM25 SM43 SM17 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A -0.075 5.073 0.999 1.177 1.140 2.652 1.897 0.900 0.661 0.831 6.264 0.747 
B -0.098 5.024 1.001 0.681 0.941 0.884 1.480 0.886 0.660 0.955 0.748 1.945 
C 0.777 2.926 0.644 1.906 0.786 1.267 2.116 0.970 0.945 9.448 0.895 2.735 
D 0.707 3.097 0.771 1.075 0.982 0.968 0.597 1.021 1.361 1.562 0.898 0.752 
E 12.773 1.897 0.587 2.824 0.590 5.992 8.186 4.373 1.005 1.176 1.806 0.761 
F 13.484 1.899 0.511 1.629 0.878 1.067 0.807 0.891 1.249 1.062 1.157 2.708 
G 8.040 1.212 1.797 0.937 1.992 0.708 0.994 0.726 0.801 0.718 1.052 2.210 
H 8.199 1.335 0.647 0.809 0.524 2.318 0.912 1.291 1.520 1.167 0.840 1.127 
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7d pre-race eHsp72 ELISA plate layout  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Std 3 Std 7 SF03 SM11 SM33 SM35 SF07 SM42 SM11 SM35 SM42 
B Blank Std 3 Std 7 SM28 SM32 SM54 SM52 SM47 SM31 SM30 SM15 SM07 
C S0 Std 4 SM31 SM55 SM30 SF09 SM15 SM26 SF11 SM06 SM18 SM40 
D S0 Std 4 SM07 SM49 SM51 SM48 SM24 SM08 SM39 SM38 SM50 SM13 
E Std 1 Std 5 SF11 SM45 SM06 SF02 SM18 SF04 SF03 SM33 SF07 SM28 
F Std 1 Std 5 SM40 SM53 SF10 SM04 SM05 SM27 SM55 SF09 SM26 SM49 
G Std 2 Std 6 SM39 SF05 SM38 SM02 SM50 SM10 SM45 SF02 SF04 SM53 
H Std 2 Std 6 SM13 SM44 SM17 SM36 SM19 SM03 SF05 SM02 SM10 SM44 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A -0.067 4.358 0.958 0.829 0.725 2.690 1.022 0.598 0.693 0.761 1.112 0.658 
B -0.049 4.269 0.942 0.783 1.001 0.948 0.981 0.697 0.710 1.973 0.726 0.845 
C 0.816 2.394 0.662 1.780 1.922 0.866 0.733 0.751 1.013 1.075 3.088 1.192 
D 0.828 2.421 0.809 0.986 0.819 2.938 1.133 2.155 0.777 1.157 0.850 3.776 
E 12.867 1.615 0.921 0.986 1.048 1.870 3.007 0.578 0.887 3.137 0.667 0.810 
F 13.003 1.540 1.374 6.865 1.759 0.821 1.133 3.601 1.717 0.941 0.793 1.094 
G 8.307 1.074 0.714 0.641 0.925 0.716 0.842 1.593 1.164 1.768 0.668 7.737 
H 7.793 1.110 3.210 0.865 1.217 0.673 1.586 0.676 0.828 0.765 1.896 1.055 
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6-8h post race eHsp72 ELISA plate layout 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Std 3 Std 7 SM28 SM13 SM03 SF03 SM48 SM38 SM30 SM02 SM49 
B Blank Std 3 Std 7 SM27 SM11 SM02 SF02 SM47 SM36 SM24 SF10 SM47 
C S0 Std 4 SM36 SM26 SM10 SF11 SM55 SM45 SM33 SM18 SM28 SM44 
D S0 Std 4 SM35 SM24 SM08 SF10 SM54 SM44 SM30 SM15 SF07 SM42 
E Std 1 Std 5 SM33 SM19 SM07 SF09 SM53 SM43 SM27 SM11 SF04 SM39 
F Std 1 Std 5 SM32 SM18 SM06 SF07 SM52 SM42 SM29 SM08 SF02 SM38 
G Std 2 Std 6 SM31 SM17 SM05 SF05 SM50 SM40 SF11 SM06 SM54 SM43 
H Std 2 Std 6 SM30 SM15 SM04 SF04 SM49 SM39 SF11 SM04 SM52 SF09 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.034 6.173 1.967 1.911 5.662 1.608 2.092 7.299 2.499 3.293 1.908 2.551 
B 0.034 6.588 1.857 8.091 1.548 1.613 3.273 1.85 1.704 2.146 3.085 1.672 
C 1.893 4.537 1.448 1.868 2.667 1.852 3.814 2.518 5.757 5.742 2.291 3.374 
D 1.95 4.437 1.96 2.204 4.26 2.8 1.937 3.193 3.415 1.917 1.659 2.537 
E 13.26 2.91 5.746 2.789 2.162 1.601 12.78 1.56 7.695 1.864 1.785 2.322 
F 15.08 3.024 1.927 7.526 2.103 1.492 2.211 1.882 2.211 4.058 3.537 2.156 
G 10.43 2.575 1.536 2.323 2.217 1.568 1.775 2.224 2.497 2.2 1.938 2.079 
H 8.36 2.032 2.887 2.107 2.217 1.576 2.782 2.263 2.67 2.482 2.724 2.374 
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7d post-race eHsp72 ELISA plate layout 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Std 3 Std 7 SM11 SM45 SM39 SM47 SF02 SM54 SF04 SM30 SM08 
B Blank Std 3 Std 7 SM40 SM48 SM10 SF05 SM42 SM17 SM50 SM02 SM18 
C S0 Std 4 SF02 SM54 SF04 SM30 SM08 SF10 SF09 SM33 SM19 SM26 
D S0 Std 4 SM42 SM17 SM50 SM02 SM18 SF07 SM06 SM32 SM28 SM24 
E Std 1 Std 5 SF10 SF09 SM33 SM19 SM26 SF03 SM53 SF11 SM13 SM55 
F Std 1 Std 5 SF07 SM06 SM32 SM28 SM24 SM35 SM52 SM27 SM05 SM43 
G Std 2 Std 6 SF03 SM53 SF11 SM13 SM43 SM11 SM45 SM39 SM47 SM47 
H Std 2 Std 6 SM35 SM52 SM27 SM05 SM55 SM40 SM48 SM10 SF05 SF03 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A -0.048 4.320 1.050 0.744 1.087 0.916 0.748 1.809 1.018 0.754 2.068 2.278 
B -0.024 4.454 1.122 1.092 3.812 1.669 0.903 0.785 1.118 1.016 0.945 2.757 
C 0.805 3.036 1.590 0.881 0.676 2.071 2.096 2.341 0.820 3.612 1.745 0.839 
D 0.905 3.121 0.746 1.066 0.917 0.832 4.237 0.663 0.881 0.995 0.871 1.574 
E 13.827 1.998 2.073 0.770 4.005 1.936 0.955 0.767 8.223 1.137 3.648 1.543 
F 12.629 1.971 0.716 0.941 1.111 0.906 1.387 0.975 0.971 3.604 1.354 0.861 
G 8.554 1.277 0.848 9.854 1.016 4.209 0.844 0.853 0.988 1.068 0.725 0.751 
H 7.526 1.439 0.961 1.139 4.108 1.364 2.108 1.372 4.531 2.072 0.928 1.032 
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Baseline LPS ELISA plate layout   
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F SM24 SM24 SM26 SM26 SF07 SF07 SM33 SM33 SM38 SM38 
C SM31 SM31 SM18 SM18 SM10 SM10 SF03 SF03 SM30 SM30 SF02 SF02 
D SM35 SM35 SM06 SM06 SF09 SF09 SM55 SM55 SM03 SM03 SM36 SM36 
E SM39 SM39 SM27 SM27 SM49 SM49 SM07 SM07 SF05 SF05 SM54 SM54 
F SM28 SM28 SM50 SM50 SM15 SM15 SM45 SM45 SM43 SM43 SM17 SM17 
G SM05 SM05 SF11 SF11 SM13 SM13 SM52 SM52 SM48 SM48 SM40 SM40 
H SF10 SF10 SM32 SM32 SM44 SM44 SF04 SF04 SM53 SM53 SF06 SF06 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F 6.761 6.850 5.782 6.405 6.939 10.052 5.871 10.319 8.540 9.074 
C 13.433 13.611 14.500 14.500 10.319 10.141 8.006 8.006 11.832 8.718 11.654 11.654 
D 11.120 11.476 7.028 7.473 12.632 14.678 11.387 11.298 16.458 18.237 5.338 4.181 
E 16.013 17.525 10.230 14.234 7.473 7.473 13.255 11.921 15.212 16.013 11.565 9.074 
F 13.789 13.789 13.789 13.967 9.875 9.608 13.611 13.878 8.718 7.028 6.939 7.206 
G 9.964 9.163 -1.156 3.025 10.408 10.675 8.362 7.917 7.917 10.675 3.914 3.736 
H 8.629 9.252 8.896 8.362 6.316 7.295 54.355 56.223 11.298 9.430 SF06 SF06 
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Pre-race LPS ELISA plate layout  
 
 
Pre-race 1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F SM42 SM42 SM03 SM03 SM10 SM10 SM27 SM27 SF04 SF04 
C SM08 SM08 SM47 SM47 SM26 SM26 SF07 SF07 SM19 SM19 SM50 SM50 
D SM05 SM05 SM02 SM02 SM18 SM18 SM24 SM24 SM15 SM15 SM04 SM04 
E SF02 SF02 SM48 SM48 SF09 SF09 SM06 SM06 SF10 SF10 SM45 SM45 
F SM15 SM15 SM55 SM55 SM28 SM28 SF03 SF03 SM36 SM36 SF05 SF05 
G SM07 SM07 SM52 SM52 SM53 SM53 SM31 SM31 SM35 SM35 SM11 SM11 
H SM40 SM40 SM17 SM17 SM44 SM44 SF11 SF11 SM38 SM38 SM30 SM30 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F 11.921 14.856 14.500 15.123 15.123 13.789 9.786 13.433 69.300 70.456 
C 5.871 7.028 11.565 11.476 12.188 10.586 4.181 5.249 24.286 9.430 12.188 13.878 
D 8.273 9.252 9.074 10.942 19.037 18.593 8.273 7.828 8.362 8.273 10.141 9.608 
E 11.387 12.632 15.924 16.902 24.642 24.642 12.365 8.896 12.810 10.586 13.700 13.255 
F 8.362 8.273 9.875 12.188 17.881 18.860 10.497 9.430 14.500 16.902 20.995 20.194 
G 6.138 7.473 9.875 12.632 26.866 27.844 17.792 13.967 9.519 8.896 7.651 6.850 
H 3.203 3.736 7.295 8.540 11.298 11.476 8.807 8.451 12.010 10.675 8.896 7.206 
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6-8h Post-race LPS ELISA plate layout  
 
Post-race 1 2 3 4 5 6 7 8 9 10 11 12 
A SF02 SF02 SF03 SF03 SF04 SF04 SF05 SF05 SF07 SF07 SF09 SF09 
B SF10 SF10 SF11 SF11 SM02 SM02 SM03 SM03 SM04 SM04 SM05 SM05 
C SM06 SM06 SM07 SM07 SM08 SM08 SM10 SM10 SM11 SM11 SM13 SM13 
D SM15 SM15 SM17 SM17 SM18 SM18 SM19 SM19 SM24 SM24 SM26 SM26 
E SM27 SM27 SM28 SM28 SM30 SM30 SM31 SM31 SM32 SM32 SM33 SM33 
F SM35 SM35 SM36 SM36 SM38 SM38 SM39 SM39 SM40 SM40 SM42 SM42 
G SM43 SM43 SM44 SM44 SM45 SM45 SM47 SM47 SM48 SM48 SM49 SM49 
H SM50 SM50 SM52 SM52 SM53 SM53 SM54 SM54 SM55 SM55 Blank Blank 
 
 
Post-race 1 2 3 4 5 6 7 8 9 10 11 12 
A 31.581 33.716 6.227 6.049 22.685 23.130 7.828 9.074 11.031 9.875 8.896 9.697 
B 13.344 13.789 2.224 4.448 11.298 10.853 8.540 9.163 4.359 4.715 6.494 5.960 
C 4.626 4.893 25.087 24.375 8.629 10.230 3.203 4.626 4.537 4.537 15.924 18.237 
D 8.273 9.252 5.427 4.626 13.700 11.743 10.586 11.031 10.319 8.273 3.825 4.181 
E 9.252 7.740 15.746 13.344 -2.669 6.138 6.227 5.160 8.718 7.384 0.623 2.580 
F 2.669 2.580 1.512 1.690 4.804 5.427 7.740 7.117 11.209 8.273 11.654 7.473 
G 23.219 19.660 12.632 12.010 17.703 16.280 3.825 1.868 3.114 2.758 5.160 5.604 
H 6.227 5.427 18.682 19.660 8.540 8.896 6.850 4.982 18.771 19.927 Blank Blank 
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7d post-race LPS ELISA plate layout  
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F SF02 SF02 SM42 SM42 SF09 SF09 SM17 SM17 SM54 SM54 
C SM40 SM40 SM11 SM11 SM35 SM35 SF03 SF03 SF07 SF07 SF10 SF10 
D SM06 SM06 SM53 SM53 SM52 SM52 SM45 SM45 SM48 SM48 SF04 SF04 
E SM50 SM50 SM33 SM33 SM32 SM32 SM13 SM13 SM28 SM28 SM19 SM19 
F SM02 SM02 SM30 SM30 SM10 SM10 SM39 SM39 SM27 SM27 SF11 SF11 
G SM05 SM05 SM47 SM47 SF05 SF05 SM08 SM08 SM18 SM18 SM26 SM26 
H SM24 SM24 SM43 SM43 SM55 SM55 SF02 SF02 SF09 SF09 SM06 SM06 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A Blank Blank A A B B C C D D E E 
B F F 12.010 13.077 20.817 21.528 17.258 19.215 7.028 6.939 12.899 13.522 
C 8.629 7.917 4.003 3.114 11.031 12.188 5.338 4.626 8.985 9.697 5.604 5.604 
D 5.427 5.338 14.945 14.856 13.522 14.412 12.010 12.010 4.270 3.203 11.209 10.141 
E 19.660 25.887 50.707 53.109 23.752 25.532 9.697 6.761 12.810 12.188 11.031 6.049 
F 18.682 19.660 12.810 13.255 4.092 4.092 13.700 14.500 4.359 3.825 0.801 2.402 
G 18.237 19.037 6.405 5.782 9.964 14.323 9.519 9.964 19.126 20.016 4.537 3.114 
H 7.740 7.828 6.850 7.206 8.807 8.540 12.010 13.077 17.258 19.215 5.427 5.338 
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Appendix H  
 
eHsp72 graph for linearity  
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Appendix I  
 
LPS graph for linearity  
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